GENES ENCODING BRANCHED-CHAIN ALPHA-KETOACID DEHYDROGENASE COMPLEX FROM STREPTOMYCES AVERMITILIS

Abstract: The present invention relates to novel DNA sequences that encode for the branched-chain alpha-ketoacid dehydrogenase complex of an organism belonging to the genus Streptomyces and to novel polypeptides produced by the expression of such sequences. It also relates to novel methods of enhancing the production of natural avermectin, of producing a Streptomyces avermitilis bkd mutant and of producing novel avermectins through fermentation.

Description: GENES ENCODING BRANCHED-CHAIN ALPHA-KETOACID DEHYDROGENASE COMPLEX FROM STREPTOMYCES AVERMITILIS Background of the Invention The present invention relates to novel DNA sequences that encode for a branched-chain alpha-ketoacid dehydrogenase (BCKDH) complex of an organism belong to the genus Streptomyces. It also relates to the production of a Streptomyces avermitilis branched-chain alpha-ketoacid dehydrogenase (bkd)-deficient mutant by genetic engineering technology. The bkd-deficient mutant lacks branched-chain alpha- ketoacid dehydrogenase activity, and is useful for the fermentative production of novel (non-natural) avermectins. S. avermitilis naturally produces eight distinct but closely related antiparasitic polyketide compounds named avermectins. The avermectin complex produced by S^ avermitilis has four major components, A1a, A2a, B1a, and B2a, and four minor components, A1b, A2b, B1 b, and B2b. The structure of the various components are depicted below. The avermectin polyketide structure is derived from seven acetate, five propionate molecules, and one alpha-branched-chain fatty acid molecule, which is either S(+)-2-methylbutyric acid or isobutyric acid. The designations "A" and "B" refer to avermectins wherein the 5-substituent is methoxy or hydroxy, respectively. The numeral "1" refers to avermectins wherein a double bond is present at the 22-23 position, and numeral "2" to avermectins having a hydrogen at the 22-position and hydroxy at the 23-position. Lastly, the C-25 has two possible substituents: the sec-butyl substituent (derived from the incorporation of S(+)-2-methylbutyric acid) is present in the avermectin "a" series, and the isopropyl substituent (derived from the incorporation of isobutyric acid) is present in the avermectin "b" series (for a review see Fisher, M.H. and Mrozik, H., 1984, "Macrolide Antibiotics", Academic Press, chapter 14). By "natural" avermectins is meant those avermectins produced by j avermitilis wherein the 25-position substituent is, as mentioned above, either isopropyl or sec-butyl. Avermectins wherein the 25-position group is other than isopropyl or sec-butyl are referred to herein as novel or non-natural avermectins. One metabolic route to the natural alpha-branched-chain fatty acids in their CoA form is from the alpha branched-chain amino acids isoleucine and valine through a branched-chain amino acid transaminase reaction followed by a branched-chain alpha-ketoacid dehydrogenase reaction. (Alternatively, branched-chain fatty acyl-CoA derivatives can arise from branched-chain alpha-ketoacids produced by de novo synthesis). These metabolic pathways are depicted below. CH,CHCH(NHp)C00H) CH 3 CH 2 CHCH(NH,)C00H I CH 3 CH 3 Val ine Isoleuc ine sobulyry 1 -Cofl e-flethylbutyryl-CoH Degradation palhuay (Rcetyl-CoR, Propi ony1 -CoR , flethylmalonyl-Coa) fivermectin Biosynthesis Cofl exogenous branched-chain fatly acid novo synthesis A mutant of S. avermitilis with no detectable branched-chain alpha-ketoacid dehydrogenase (BCKDH) activity in the last mentioned enzyme was previously isolated (Hafner et al., 1988, European Patent EP 284,176, which issued on October 20, 1993). The mutant was isolated following standard chemical mutagenesis of ^ avermitilis strain ATCC 31272 in a screen searching for the absence of 14 CO 2 production from 14 C-1 labeled 2-oxoisocaproic acid substrate (leucine analog). The mutant is unable to synthesize natural avermectins except when the S(+)-2-methylbutyric acid or isobutyric acid or a precursor bearing the isopropyl or sec-butyl (S-form) group is added to the medium in which the mutants are fermented. The mutant is also capable of producing novel (non-natural) avermectins when fermented under aqueous aerobic conditions in a nutrient medium containing an exogenously added alternative carboxylic acid, such as cyclohexane carboxylic acid (CHC), or a precursor thereof, as indicated above. To clone the genes that encode the branched-chain alpha-ketoacid dehydrogenase complex of S_, avermitilis is highly desirable. Manipulation of these genes through recombinant DNA techniques should facilitate the production of natural and novel avermectins. For certain strains, increased titer of natural avermectins would be anticipated by increasing the copy number of the bkd genes. In addition, generation of an irreversibly blocked bkd strain, having BCKDH activity permanently deleted or modified by gene replacement, would be an improved alternative to the bkd mutant which was obtained, as mentioned before, by chemical mutagenesis. The alpha-ketoacid dehydrogenase multienzyme complexes - the branched- chain alpha-ketoacid dehydrogenase (BCKDH) complex, the pyruvate dehydrogenase (PDH) complex, and the alpha-ketoglutarate dehydrogenase (KGDH) complex catalyze the oxidative decarboxylations of branched-chain alpha-ketoacids, pyruvate, and alpha-ketoglutarate, respectively, releasing CO2 and generating the corresponding Acyl-CoA and NADH (Perham, R. N., 1991 , Biochemistry. 30: 8501-8512). Each complex consists of three different catalytic enzymes: decarboxylase (E1), dihydrolipoamide acyltransferase transacylase (E2), and dihydrolipoamide dehydrogenase (E3). Branched-chain alpha-ketoacid dehydrogenase (BCKDH) is a multienzyme complex composed of three functional components, E1 , the decarboxylase, E2, the transacylase, and E3, the lipoamide dehydrogenase. The purified complexes from Pseudomonas putida, Pseudomonas aeruginosa. and Bacillus subtilis. are composed of four polypeptides. The purified mammalian complexes also consist of four polypeptides, E1 alpha, Elbeta, E2, and E3. An alpha-ketoacid dehydrogenase complex has been isolated from Bacillus subtilis which has both pyruvate and branched-chain alpha-ketoacid dehydrogenase activities. This dual function complex oxidizes both pyruvate branched-chain alpha-ketoacids for membrane phospholipids. Cloning of prokaryotic branched-chain alpha-ketoacid dehydrogenase genes has been reported for Pseudomonas and Bacillus. In these systems it was found that the genes encoding the BCKDH were clustered in an operon. The genes of the BCKDH complex of Pseudomonas putida have been cloned and the nucleotide sequence of this region determined (Sykes et al., 1987, J. Bacteriol., 169:1619-1625. and Burns et al., 1988, Eur. J. Biochem. 176:165-169, and 176:311-317). The molecular weight of E1 alpha is 45289, of Elbeta is 37138, of E2 is 45134, and of E3 is 48164. The four genes are clustered in the sequence: E1 alpha, Elbeta, E2, and E3. Northern blot analysis indicated that expression of these four genes occurs from a single mRNA and that these genes constitute an operon. There is a typical prokaryotic consensus promoter immediately preceding the start of the E1 alpha coding region that permits the constitutive expression of the Pseudomonas bkd genes. The initiator codon for the E1 beta coding region is located only 40 nucleotides downstream from the end of the E1 alpha open reading frame (ORF). In contrast, there is no intergenic space between the Elbeta and E2 ORFs since the stop codon for the Elbeta ORF is the triplet immediate preceding the initiator codon of the E2 ORF. The intergenic space between the E2 and the E3 ORFs is reduced to only 2 nucleotides. Therefore, the Pseudomonas bkd genes are tightly linked. Similarly, the operon coding for the Bacillus subtilis BCKDH/PDH dual complex has been cloned (Hemila et al., 1990, J. Bacteriol., 172:5052-5063). This operon contains four ORFs encoding four proteins of 42, 36, 48, and 50 kilodaltons (kDa) in size, shown to be highly homologous to the E1 alpha, Elbeta, E2, and E3 subunits of the Pseudomonas bkd cluster. The genes encoding the alpha and beta subunits of the E1 component of the dual BCKDH/PDH multienzyme complex from Bacillus stearothermophilus have also been cloned and sequenced (estimated molecular weights of the alpha and beta subunits are approximately 41 ,000 and 35,000, respectively) (Hawkins et al., 1990, Eur. J. Biochem.. 191 :337-346). Additionaliy, the sequences of a number of eukaryotic E1 alpha and beta BCKDH subunits (human, bovine, and rat) have been disclosed. Recently, an amino acid sequence comparison of all the published sequences known for both E1 alpha and Elbeta components of the PDH and the BCKDH complexes from multiple species was performed by computer analysis (Wexler et a[., 1991 , FEBS Letters. 282:209-213). Interestingly, several regions of the alpha and beta subunits were identified that are highly conserved not only in all PDHs so far described, but also in both prokaryotic and eukaryotic BCKDH complexes. Also, recently, three genes encoding, respectively, the alpha (bkdA) and beta (bkdB) subunits of the E1 component, and the E2 (bkdC) component of a BCKDH complex from Streptomyces avermitilis were cloned, sequenced, and analyzed by using a heterologous gene expression system (Denoya, CD., 1993, "Cloned genes encoding branched-chain alpha-ketoacid dehydrogenase complex from Streptomyces avermitilis". U.S. Patent Application 08/100,518, filed July 30, 1993). DNA sequence analysis showed the presence of putative transcriptional promoter sequences and bkd structural genes arranged as a cluster organized as follows: promoter sequence, E1- alpha (bkdA), E1-beta (bkdB). and E2 (bkdC) open reading frames. Additionally, the complete S. avermitilis bkdABC gene cluster was cloned downstream of the strong Escherichia coli T7 promoter for expression in an E. coli host. Similarly, the E1 -alpha and E1-beta open reading frames (ORFs) were also cloned, either separately or together, downstream of the T7 promoter and each construction was tested for expression. These studies demonstrated that at least 2 open reading frames of the S. avermitilis bkd gene cluster (E1 -alpha [bkdA] and E1 -beta [bkdB]) were fully translatable when expressed in E. coli. In addition, enzymatic assays aimed to analyze specifically the E1 component of the BCKDH complex confirmed conclusively that two of the recombinant E. coli clones, one carrying the whole bkd gene cluster and other carrying together the E1 -alpha and the E1-beta ORFs, contained E1 BCKDH-specific enzyme activity. The present invention relates to the molecular cloning and analysis of a second cluster of novel genes encoding branched-chain alpha-ketoacid dehydrogenase (BCKDH) of Streptomyces avermitilis. The cluster contains at least 3 genes (bkdF, bkdG. and bkdH) encoding, respectively, for the E1 -alpha, E1-beta and E2 subunits of the S. avermitilis BCKDH complex. The bkd gene cluster disclosed here is located approximately 12 kilobases (kb) downstream of the first bkd cluster (bkdA. bkdB. and bkdC genes) recently reported (Denoya, C. D., 1993, U.S. Patent Application 08/100,518, filed July 30, 1993). Both clusters share a similar gene organization, and they are oriented in the same direction on the S. avermitilis chromosome. The corresponding structural genes in both clusters, though highly homologous, are different. In addition, this invention also relates to the construction of a bkd mutant by genetic engineering technology. The bkd mutant, which carries a chromosomal deletion affecting the bkdF gene, lacks branched-chain alpha-ketoacid dehydrogenase activity, is unable to grow on isoleucine, leucine, and valine as sole carbon sources, and is also incapable of making natural avermectins in a medium lacking both S-2- methylbutyric and isobutyric acids. The mutant disclosed here is useful to produce novel (non-natural) avermectins through fermentation in a medium containing an appropriate alternative carboxylic acid, such as cyclohexane carboxylic acid (CHC). Further, this invention relates to the construction of a mutant that carries a chromosomal deletion affecting both the bkdF gene and the bkdABC gene cluster. Streptomyces has one major genetic linkage group, one chromosome, that is frequently present in multiple copies per hyphal compartment but is present only as a single copy in the spores. The Streptomyces genome is characteristically large among prokaryotes (5 x 10 3 to 7 x 10 3 kilobases [kb]) (Gladek, A., and Zakrzewska, J., 1984, FEMS Microbiol. Lett.. 24:73-76), about two times the size of that of E. coli. One particularly interesting aspect of the Streptomyces genetics is the frequent chromosomal rearrangements involving extensive deletions which are frequently accompanied by intense DNA amplifications (Birch A. et a[., 1990, J. Bacteriol.. 172:4138-41421. Amplifications and deletion events in Streptomyces are two to three orders of magnitude larger than similar events in E. coli and B. subtilis. Deletions constituting 18% of the chromosome and amplifications representing 45% of the genome have been reported. Despite their inherent long term instability, duplications of certain genes arise with frequencies as high as one in 10 4 cells. Such duplications are usually generated by illegitimate crossing-over events that involve short, partially homologous sections of DNA in dividing daughter chromosomes. Such duplication events, by creating new stretches of DNA on the same chromosome, automatically tend to be followed by further gene amplification or elimination events. Multiple copies not only of the same gene but also of two different genes with highly similar structures will tend to recombine and to produce deletions. A gene's inherent stability thus demands that it not be too similar to any other penes. The presence of multiple copies of a gene or group of genes in Streptomyces is not unusual. A modular organization of genes required for synthesis of the polyketide portion of the macrolide antibiotic erythromycin in Saccharopolvspora ervthraea has been reported (Donadio et al., 1991 , Science. 252:675-679). We have discovered that Streptomyces avermitilis has at least 2 clusters of bkd genes: one cluster comprising bkdA. bkdB. and bkdC genes, the other cluster comprising bkdF, bkdG, and bkdH genes. We speculate that both the bkdABC (disclosed previously in U.S. Patent Application 08/100,518, filed July 30, 1993 and referred to above) and the bkdFGH gene clusters disclosed here arose by gene duplication in S. avermitilis. and that the 2 copies accumulated, through mutations, enough differences to assure survival (avoiding recombination/deletion events). In addition to disclosing a second novel cluster of genes encoding BCKDH, we also disclose the construction of a Streptomyces avermitilis bkdF mutant by genetic engineering technology. The bkdF mutant lacks branched-chain alpha-ketoacid dehydrogenase activity, is unable to grow with isoleucine, leucine, and valine as sole carbon sources, and is also incapable of making natural avermectins in a medium lacking both S-2-methylbutyric and isobutyric acid. The bkdF mutant is useful for producing novel avermectins through fermentation in a medium containing an appropriate alternative carboxylic acid, such as cyclohexane carboxylic acid (CHC). We also disclose the construction of a mutant that carries a chromosomal deletion affecting both the bkdF gene and the bkdABC gene cluster. Generation of Streptomycetes mutants using chemical and physical mutagens is an important technology to analyze gene function and regulation, and to develop improved industrial strains. Recent developments in Streptomyces gene cloning have resulted in the possibility of manipulating by recombinant DNA technology a myriad of cloned genes such as resistance, biosynthetic, and regulatory genes, and to elucidate gene organization and regulation. Another mutagenic approach, gene replacement, was successfully applied in Saccharomvces cerevisiae. Escherichia coli. and Bacillus subtilis (Scherer, S. and R. W. Davis, 1979, Proc. Natl. Acad. Sci. U.S.A.. 76: 4951-4955; Shortle, D., et al., 1982, Science. 217:371-373; Stahl, M.L, and Ferrari, E., 1984, J, Bacteriol., 158:411-418), and also in Saccharopolyspora ervthraea (Weber, J.M., and Losick, R., 1988, Gene, 68:173-180) and several streptomycetes species. This technique allows the introduction of an in vitro generated mutation carried on a plasmid into the chromosome of the host strain. This approach is based on the findings that recombination occurs between the host chromosome and a plasmid containing a homologous region. Gene replacement in S. avermitilis occurs by means of homologous recombination between cloned sequences carried in the vector and their chromosomal counterparts. Presumably, two crossovers occurring simultaneously, or a single crossover leading to integration and a subsequent resolution step where the integrated plasmid is excised, cause reciprocal exchange between the cloned and resident sequences. We have observed both double and single crossover events in S. avermitilis. Both mechanisms, double crossover and single crossover, followed by excision result in the same product. By using this approach we were able to disrupt the E1 -alpha open reading frame of the bkdF gene of S. avermitilis. The disruption involved a chromosomal deletion of about 1.4 kb affecting the 5'-harf of the gene encoding the E1 -alpha subunit of the BCKDH complex. The resulting mutant strain, which exhibits all the characteristic phenotypical traits of a bkd mutant, is stable and can be used to generate valuable novel avermectins by fermentation. All publications cited in this document are incorporated herein by reference in their entireties. Glossary Technical terms used throughout this application are well known to those skilled in the art of molecular genetics. Terms frequently utilized in this invention are defined below: Amplification: Refers to the production of additional copies of a chromosomal sequence, found as either intrachromosomal or extrachromosomal DNA. Antibiotic Resistance Gene: DNA sequence that conveys resistance to an antibiotic when introduced into a host cell that is naturally sensitive to that particular antibiotic. Also known as antibiotic marker. Clone: Large number of cells or molecules identical with a single ancestor. Cloning Vector: Any plasmid into which a foreign DNA may be inserted to be cloned. It carries foreign DNA into a host bacterial cell upon transformation. CoA: Coenzyme A. Cohesive End Seguence (Cos): DNA sequence derived from bacteriophage lambda allowing in vitro packaging. Cosmid: Plasmid into which bacteriophage lambda cos sites have been inserted; as a result, the plasmid DNA (carrying foreign DNA inserts) can be packaged in vitro in the phage coat. cRNA: Single-stranded RNA complementary to DNA, synthesized from the latter by in vitro transcription. Crossover: Refers to the point where a reciprocal exchange of material between a cloned sequence and its chromosomal counterpart occurs. Dalton: unit of mass commonly used in connection with molecular dimensions corresponding to one hydrogen atom. DNA Lioation: The formation of a chemical bond linking two fragments of DNA. Double Crossover Events: Two crossovers occurring either simultaneously or in succession. As a result, a reciprocal exchange between the cloned and resident sequences occurs. Gene Cluster: A group of genes physically close on the chromosome. Gene Replacement: Technique which permits the introduction of an jn vitro derived mutation carried on a plasmid into the chromosome. The replacement occurs when the host chromosome and a plasmid containing a region homologous to it recombine. Genome: Entire chromosome set. The sum total of all of an individual's genes. Hybridization. Colony Hybridization: Technique used to identify bacterial colonies carrying chimeric vectors whose inserted DNA is similar to some particular sequence. Hvpha: The principal element of the growing or vegetative form of a mold. Hyphae are tubular structures, about 2 to 10 microns in diameter, that form a mass of intertwining strands called mycelium. kb: Abbreviation for 1 ,000 base pairs of DNA or RNA. Linker: Short synthetic duplex oligodeoxynucleotide containing the target site for one or more restriction enzymes. It is added to a vector to create a novel polylinker or multiple cloning site (MCS). NADH: Reduced nicotinamide adenine dinucleotide. Nucleotide: building block, or monomeric unit, of nucleic acids. Oligonucleotide: A short chain of nucleotides. Operon: A complete unit of bacterial gene expression and regulation, including structural genes, regulator genes, and control elements in DNA recognized by regulator gene product (s). Plasmid: Autonomous, self-replicating, extrachromosomal circular DNA. Plasmid Copy Number: Number of plasmid molecules maintained in bacteria for every host chromosome. Primer: Short sequence of DNA or RNA that is paired to one strand of DNA and provides a free 3'-hydroxy end at which a DNA polymerase starts synthesis of a deoxyribonucleotide chain. Prokaryotic Cells: The small, relatively simple cells comprising most microorganisms. Promoter: Region of DNA responsible for the initiation of transcription. Restriction Enzyme: Enzyme that recognizes a specific short sequence of DNA and cleaves it. Restriction Recognition Sequence: DNA sequence specifically recognized by a particular restriction enzyme. Also known as target site. Shuttle Vector: Bifunctional cloning vector able to replicate in one or more alternative hosts (e.g., E. coli and Streptomyces). Single Crossover Event: Single reciprocal genetic recombination occurring at a single point. It causes integration of an incoming circular plasmid or phage vector and a duplication in the homologous chromosome sequence. Southern Blotting: The procedure for transferring denatured DNA from an agarose gel to a nitrocellulose filter where it can be hybridized with a complementary nucleic acid probe. Subcloninα: Transferring cloned fragments of DNA from one type of vector to another, for example, from a recombinant cosmid to a plasmid. The new recombinant plasmid is then transformed into an appropriate host cell to produce a subclone strain. Transformation of Bacterial Cells: Describes the acquisition of new genetic markers by incorporation of added DNA. Summarv of the Invention This invention relates to an isolated DNA segment that encodes for a branched- chain alpha-ketoacid dehydrogenase complex of an organism belonging to the genus Streptomyces. This invention also relates to an isolated DNA segment, as described above, that further comprises a DNA region that regulates the expression of such branched-chain alpha-ketoacid dehydrogenase complex. This invention also relates to an isolated DNA segment that encodes for a Streptomyces avermitilis branched-chain alpha-ketoacid dehydrogenase complex. This invention also relates to a DNA segment comprising the DNA sequence of SEQUENCE ID NO. 1 , SEQUENCE ID NO. 2, SEQUENCE ID NO. 3 or SEQUENCE ID NO. 4, as described below, or an allelic variation of such sequence. It also relates to a DNA segment that is a subset of the foregoing DNA segment and functionally equivalent to it. This invention also relates to: (a) recombinant DNA comprising the DNA sequence of SEQUENCE ID NO. 1 , SEQUENCE ID NO. 2, SEQUENCE ID NO. 3 or SEQUENCE ID NO. 4, or an allelic variation of such sequence; (b) a plasmid comprising such recombinant DNA; and (c) a host cell into which such recombinant DNA has been incorporated. This invention also relates to the genes for branched-chain alpha-ketoacid dehydrogenase complex contained in a DNA segment selected from the group consisting of pCD713, pCD740, pCD747 and pCD854, as defined below. This invention also relates to a DNA segment comprising the DNA sequence of SEQUENCE ID NO. 1 , SEQUENCE ID NO. 2, SEQUENCE ID NO. 3 or SEQUENCE ID NO. 4, or an allelic variation of such sequence. This invention also relates to a DNA segment comprising a DNA sequence that is a subset of the DNA sequence of SEQUENCE ID NO. 1 , SEQUENCE ID NO. 2, SEQUENCE ID NO. 3 or SEQUENCE ID NO. 4, or an allelic variation thereof, and that is capable of hybridizing to, respectively, SEQUENCE ID NO. 1 , SEQUENCE ID NO. 2, SEQUENCE ID NO. 3 or SEQUENCE ID NO.4, or an allelic variation thereof, when used as a probe, or of amplifying all or part of such sequence when used as a polymerase chain reaction primer. This invention also relates to a substantially purified polypeptide comprising the amino acid sequence of SEQUENCE ID NO. 5, SEQUENCE ID NO. 6, SEQUENCE ID NO. 7 or SEQUENCE ID NO. 8. This invention also relates to a method of producing a natural avermectin, comprising fermenting, under conditions and in a fermentation medium suitable for producing such natural avermectin, S^ avermitilis in which the copy number of a genomic fragment comprising one or more of the bkdF. bkdG and bkdH genes has been increased. This invention relates to a method of producing a natural avermectin, comprising fermenting . under conditions and in a fermentation medium suitable for producing such natural avermectin. S. avermitilis in which expression of a genomic fragment comprising one or more of the bkdF, bkdG and bkdH genes has been enhanced by manipulation or replacement of the genes responsible for regulating such expression. This invention also relates to a method of producing a novel avermectin, comprising fermenting, under conditions and in a fermentation medium suitable for producing such novel avermectin, S_, avermitilis in which expression of a genomic fragment comprising one or more of the bkdF. bkdG and bkdH genes has been decreased or eliminated by deletion, inactivation, replacement or other manipulation of the genes responsible for such expression. A preferred embodiment of the invention relates to the foregoing method of producing a novel avermectin, which comprises fermenting, under conditions and in a fermentation medium suitable for producing such novel avermectin, S^ avermitilis in which a genomic fragment comprising one or more of the bkdF. bkdG. and bkdH genes has been deleted or inactivated. This invention also relates to a method of producing a novel avermectin, comprising fermenting, under conditions and in a fermentation medium suitable for producing such novel avermectin, J avermitilis in which expression of a genomic fragment comprising one or more of the bkdA, bkdB and bkdC genes and one or more of the bkdF. bkdG and bkdH genes has been decreased or eliminated by deletion, inactivation, replacement or other manipulation of the genes responsible for such expression. A preferred embodiment of the invention relates to the foregoing method of producing a novel avermectin, which comprises fermenting, under conditions and in an fermentation medium suitable for producing such novel avermectin, S^ avermitilis in which a genomic fragment comprising one or more of the bkdA. bkdB and bkdC genes and one or more of the bkdF. bkdG and bkdH genes has been deleted or inactivated. Brief Description of the Drawings Figure 1 : The nucleotide sequence of the polymerase chain reaction (PCR) primers utilized to clone a fragment of the S. avermitilis bkdF gene (E1 -alpha BCKDH). Each primer was designed upon a 9-amino acid iong conserved region. The codons corresponding to each conserved amino acid are indicated above the corresponding DNA sequence. The rightward primer was designed upon a region encompassing amino acids 192-200 of the human E1 -alpha BCKDH subunit, which was used as a representative model of an E1 -alpha BCKDH subunit. The leftward primer was designed upon a region encompassing amino acids 286-293 of the E1 -alpha BCKDH subunit. At the 5'-end of the rightward primer there are two extra adenine-containing nucleotides, and two restriction enzyme recognition sequences (EcoRI and Sacl) added to facilitate the cloning of the PCR products. Similarly, at the 5 '-end of the leftward primer there are two extra adenine-containing nucleotides, and two restriction enzyme recognition sequences (BamHI and Xbal). Figure 2: Genomic restriction map, location and subclones for the Streptomyces avermitilis bkdFGH gene cluster. Also indicated is the location of the bkdABC gene cluster previously disclosed (see Denoya, CD., U.S. Patent Application 08/100,518, referred to above). The black boxes below the map indicate the location and orientation of the initial E1 -alpha-specific S. avermitilis genomic fragments cloned using PCR. Genomic subclones (derivatives of pGEM-3Z) are indicated. The location and organization of the bkdF. bkdG. and bkdH structural genes encoding E1 -alpha, E1 - beta, and E2 BCKDH subunits, respectively, are also indicated. Polarity of identified open reading frames (denoted by boxes) is left to right. Abbreviations: B, BamHI: Bg, Bglll: P, Pstl; and S, Sphl. "X" denotes the location of a transposon mini-gamma-delta- 1 insertion used to sequence DNA regions located downstream of the bkdF open reading frame, as described below. Figure 3: Nucleotide sequence and deduced translation products of the 501 -bp S. avermitilis genomic DNA fragment (CD613) cloned by PCR using the primers shown in Figure 1. This genomic fragment contains part of the bkdF gene (E1 -alpha BCKDH). Nucleotides are numbered at the top of the sequence lines. The deduced amino acid sequence is shown below the corresponding codon sequence. Figure 4: Nucleotide sequence and deduced translation products of the 201 -bp S. avermitilis genomic DNA region sequenced from the Pstl end of the pCD746 subclone using the SP6 vector primer. The deduced translation product represents part of the E1-beta component of the BCKDH complex corresponding to the bkdG gene. Nucleotides are numbered at the top of the sequence lines. The deduced amino acid sequence is shown below the corresponding codon sequence. Figure 5: Nucleotide sequence (sequence CD785) and deduced translation products of the 194-bp S. avermitilis genomic DNA region sequenced from both ends of the mini-gamma-delta-1 insertion "A3" located approximately 1.7 kb from the BamHI end containing the bkdF gene in the 4.1 kb BamHI genomic fragment. The deduced translation product represents the C-terminal end of the E1-beta component of the BCKDH complex corresponding to the bkdG gene. Nucleotides are numbered at the top of the sequence lines. The deduced amino acid sequence is shown below the corresponding codon sequence. Figure 6: Nucleotide sequence (sequence CD786) and deduced translation products of the 455-bp S. avermitilis genomic DNA region sequenced from both ends of the mini-gamma-delta-1 insertion "A5" located approximately 3 kb from the BamHI end containing the bkdF gene in the 4.1 kb BamHI genomic fragment. The deduced translation product represents the C-terminal end of the E2 component of the BCKDH complex corresponding to the bkdH gene. Nucleotides are numbered at the top of the sequence lines. The deduced amino acid sequence is shown below the corresponding codon sequence. Figure 7: Construction of the gene replacement vector pCD768 and genomic restriction map of the S. avermitilis bkdF mutant strain CD794. Plasmid pCD768 is a derivative of shuttle vector pCD262 carrying the 2.3 and the 4.1 kb BamHI S. avermitilis genomic fragments flanking the ermE marker (black arrow). Plasmid pCD761 is an intermediate construct, as described below. Genomic restriction maps (wild type and replaced strains) of the region of the S. avermitilis chromosome containing the bkdF gene are also shown. These maps were deduced from Southern hybridization analysis using the 5.0 kb Pstl genomic fragment as a probe. Abbreviations: B, BamHI: P, Pstl. Numbers above each DNA fragment indicate length in kilobases (kb). Figure 8: Restriction map of the gene replacement vector pCD768. Shaded boxes indicate: tsr - thiostrepton resistance marker; amp - ampiciliin resistance marker; "2.3" - 2.3 kb BamHI S. avermitilis genomic fragment; erm - erythromycin resistance marker; "4.1 " - 4.1 kb BamHI S. avermitilis genomic fragment. Streptomyces and E. coli origin of replication regions are also indicated. The white boxes indicate the E. coli vector region. The arrows indicate the direction of transcription and translation. Figure 9: Construction of the bkdABCF mutant. Genomic restriction map and simplified drawings of vector constructs and target genomic regions are represented. Location of bkd gene clusters, orientation of open reading frames, and abbreviations were used as described in the legend for Figure 3. Deleted segments are indicated as a gray shaded area. Continuous and dashed lines represent chromosomal and vector DNA, respectively. Thick black lines represent cloned genomic fragments used in gene replacement. Vertical arrows indicate the location of antibiotic resistance marker insertion. Detailed Description of the Invention The novel DNA sequences of this invention were cloned using a combination of two molecular genetics techniques, DNA polymerase chain reaction (PCR) and homology probing. The procedures for identifying and cloning the novel DNA sequences of this invention and the construction of a bkd mutant by gene replacement are described below. First, 2 PCR primers, named "Rightward" and "Leftward" (Figure 1), were designed upon conserved regions identified from a multiple alignment of deduced E1- alpha BCKDH peptide sequences from various species and available from the literature. A PCR product, approximately 0.55 kb long, was detected by PCR amplification of S3, avermitilis genomic DNA using both the rightward and the leftward primers. That PCR- amplified DNA fragment was subsequently cloned into the E. coli vector pGEM-3Z to produce recombinant plasmid pCD613. Subsequently, plasmid pCD613 was transformed into E. coli DH5-alpha competent cells. One transformant was selected and designated as strain CD613. DNA sequencing of cloned DNA fragment CD613 showed the existence of an open reading frame with a deduced peptide highly homologous to E1 -alpha BCKDH subunit (Figure 3). Cloned CD613 genomic DNA fragment was then used as a probe to screen a S. avermitilis chromosomal library by colony hybridization. Several cosmid clones were identified. Restriction and Southern blot analyses showed that all the selected cosmids clones carried overlapping genomic fragments. DNA sequencing of the chromosomal region, obtained from subcloned genomic DNA fragments (as fully described in Example 6), demonstrated that sequence CD613 was part of a complete bkd gene cluster. Cloned S. avermitilis bkd genes encompass a region of the chromosome approximately 4 kilobases in length (Figure 2). DNA sequence analysis showed the presence of bkd structural genes arranged as a cluster organized as follows: E1 -alpha (bkdF). E1-beta (bkdG). and E2 (bkdH) open reading frames (Figures 2-6). Next, a plasmid carrying an inactivated version of the bkdF gene was constructed. As shown in Figure 2, three adjacent BamHI restriction fragments in the S. avermitilis chromosome were mapped (from left to right): 2.3 kb, 1.4 kb and 4.1 kb. The 1.4 kb BamHI genomic fragment carries the beginning of the E1 -alpha open reading frame (ORF-1) (gene bkdF). The 4.1 kb BamHI carries the rest of the bkd gene cluster (end of bkdF. bkdG. and bkdH). Plasmid pCD768 is a derivative of shuttle vector pCD262 carrying two S. avermitilis genomic fragments (2.3 and 4.1 kb BamHI) which are adjacent on each side of the 1.4 kb BamHI fragment of the chromosome. In addition, pCD768 carries the ermE marker located between the 2.3 and the 4.1 kb BamHI fragments. The ermE marker (which confers resistance to erythromycin) lies in the opposite orientation to that of the ORF-1 (bkdF). to avoid possible difficulties caused by overexpression of downstream genes. This construct produced a 1.4 kb deletion (ORF1 will be affected) in the host genome upon recombination, as described below. Plasmid pCD768 was transformed into S. avermitilis 31272 SC2 host protoplasts. Two transformants showing resistance to both erythromycin (erm-R) and thiostrepton (tsr-R) antibiotics were selected. Transformant No. 1 (CD783) was grown in liquid medium and protoplasts were prepared and plated on agar medium containing erythromycin. Fifty clones were selected and further analyzed: 46 were erm-R, tsr-R; 4 were erm-R, tsr-S. The latter four clones exhibited a bkd-deficient phenotype, as follows: they were unable to grow on ILV minimal medium plates; they had no detectable E1 (branched-chain decarboxylase) activity; and, upon fermentation, they were unable to synthesize natural avermectins unless supplemented with either S(+)-2- methylbutyric acid or isobutyric acid (see Example 9). In addition, when CHC was added to the fermentation medium, novel avermectins (CHC-avermectins) were synthesized, demonstrating that the bkd block did not affect the avermectin biosynthetic cellular machinery. One clone out of this group of 4 (clone pp15) was formally named S. avermitilis strain CD794 and is being deposited in the American Type Culture Collection as an exemplification of this invention. Finally, Southern hybridization analysis confirmed that ORF-1 corresponding to the bkdF gene was disrupted as expected upon gene replacement in S. avermitilis ATCC 31272 SC2. A full description of the experimental steps involved in the cloning of the S. avermitilis bkd genes, and results obtained, follows: (a) Identification of conserved regions in the E1 -alpha BCKDH peptide subunit that could serve as candidate sites for binding of PCR primers. Four E1-alpha BCKDH peptide sequences from human (Fisher et a]., 1989, L Biol. Chem., 264:3448-3453). rat (Zhang et al., 1987, J. Biol. Chem.. 262:15220-15224). Pseudomonas putida (Sokatch et a]., 1988, Eur. J. Biochem.. 176:311-317). and Bacillus stearothermophilus (Perham et a]., 1990, Eur. J. Biochem.. 191 :337-346) were aligned to identify conserved regions that could serve as sequences to design corresponding PCR primers. Computer analysis to identify regions of the E1 -alpha subunit that are highly conserved in both prokaryotic and eukaryotic BCKDH complexes was done using the LineUp and Pretty programs from the GCG sequence analysis software package (GCG, Madison, Wl). Multiple alignment of the four E1 alpha BCKDH peptides showed several regions of extended homology (see Wexler, I.D. et al., 1991 , FEBS Letters. 282:209-213). The thiamin pyrophosphate binding motif (Perham et al., 1989, FEBS Letters. 255:77-82) located between human E1 -alpha amino acids 182-229, and a region encompassing phosphorylation sites 1 and 2, spanning amino acids 291- 307 were notably conserved in all four E1 -alpha BCKDH peptides analyzed. Also present was a previously described region of high homology located between amino acids 245-289. This region appears to be unique to alpha-ketoacid dehydrogenases which have both alpha and beta subunits, and is not homologous to any sequence in E. coli PDH E1 or the E1 components of E. coli and yeast alpha-ketoglutarate dehydrogenase complexes, which are dimers composed of only a single E1 polypeptide. For the above mentioned reasons, the latter region of homology has been suggested to play a role in subunit interaction (Patel et a]., 1991 , FEBS Letters. 282:209-213). Conserved regions chosen for PCR primer design encoded amino acid residues 192 to 200, and 286 to 293 of the human E1 -alpha BCKDH protein. (b) Design of novel oligonucleotides derived upon those E1 -alpha BCKDH conserved regions to be used as PCR primers. As previously discussed, two conserved regions of the E1 -alpha BCKDH subunit were selected from the multiple alignment study. The Rightward PCR primer (Figure 1) was designed upon a region encompassing amino acids 192-200 of the human E1- alpha BCKDH subunit, which was used as a representative model of an E1 -alpha BCKDH subunit. These amino acids are located within the thiamin pyrophosphate binding motif. The Leftward PCR primer (Figure 1) was designed upon a region encompassing amino acids 286-293 of the human E1 -alpha BCKDH subunit. The latter amino acid sequence comprises the end part of the subunit interaction site and the beginning of the phosphorylation site conserved regions. Streptomyces gene codon assignments were used (F. Wright and M. J. Bibb, 1992, Gene. 113:55-65). At the 5'- end of the Rightward primer there were two extra adenine-containing nucleotides, and two restriction enzyme recognition sequences (EcoRI and Sac I) to facilitate the cloning of the PCR products. Similarly, at the 5' end of the Leftward primer there were two extra adenine-containing nucleotides, and two restriction enzyme recognition sequences (BamHI and Xbal). The complete sequence of the Rightward PCR primer is: 5'-AAGAATTCGAGCTCGGCGACGGCGCCACCTCCGAGGGCGAC-3'. The complete sequence of the Leftward PCR primer is: 5'-AAGGATCCTCTAGAGGTSSWGTGGKGGCCGATSCGGWA-3'. The International Union of Biochemistry (IUB) rules of nomenclature for nucleotides were used to describe DNA sequences. Redundancies are identified following the IUB Group Codes, as follows: K=G+T, S=G-(-C, and W=A+T. Restriction recognition sequences not homologous to the E1 -alpha bkd genes and incorporated into the primers for cloning purposes are underlined (see Figure 1). (c) PCR amplification of S. avermitilis genomic DNA fragments. S. avermitilis genomic DNA was enzymatically amplified using reaction conditions appropriate for DNA with a high GC content, allowing efficient and specific amplification of streptomycetes DNA (see Example 2). PCR was performed using the primer combination described above (Rightward primer, 5'- AAGAATTCGAGCTCGGCGACGGCGCCACCTCCGAGGGCGAC-3', and Leftward primer, 5'-AAGGATCCTCTAGAGGTSSWGTGGKGGCCGATSCGGWA-3'). The amplification products were size fractionated by agarose gel electrophoresis. Under the PCR conditions described above, a single DNA band (approximately 550 base pairs long) was detected when using this primer combination. (d) Cloning of amplified genomic DNA fragment into Escherichia coli cloning vector, and subsequent transformation into E. coli host. As mentioned before, an EcoRI restriction site was incorporated into the Rightward PCR primer for cloning convenience, and a Xbal restriction site was present in the 5' end of the Leftward primer. The 0.55 kb PCR fragment was recovered from the agarose gel by electroelution and it was digested with both EcoRI and Xbal restriction enzymes. Many recombinant clones were recovered after ligating the specific fragment into a linearized E. coli vector (pGEM-3Z), to produce recombinant plasmid pCD613, and transforming it into E. coli competent cells. One transformant was selected for further characterization and it was designated as strain CD613. Confirming restriction analysis showed that plasmid pCD613, isolated from E. coli strain CD613, indeed contained the 0.55 kb S. avermitilis insert. (e) DNA seguencing of cloned fragment and identification of bkd-specific seouences. The 0.55 kb insert present in plasmid pCD613 was sequenced by a double- stranded sequencing procedure using a pair of vector primers (see Example 6A). In addition, a 0.35 kb Sail fragment, which is located internally in the 0.55 kb PCR insert, was subcloned into bacteriophage M13, and was sequenced by a single-stranded sequencing protocol (see Example 6B). DNA sequencing was performed by the dideoxynucleotide-chain termination method, with a single-stranded DNA template and the TaqTrack kit (Promega). Codon preference analysis (GCG sequence analysis software package, Madison, Wl) of the DNA sequencing data showed the existence of an open reading frame having the expected codon usage for a streptomycetes gene. Next, the putative open reading frame was translated into an amino sequence using the Seq and Translate programs of the IntelliGenetics Suite software (IntelliGenetics Inc., Mountain View, California). Finally, data bank similarity searches with the query peptide sequence were run using the FASTDB program of the IntelliGenetics software. All data bank searches, searching either DNA data banks (GenBank ® , National Institute of Health, and European Molecular Biology Laboratory (EMBL), Heidelberg, Germany) or protein data banks (PIR and Swiss-Prot), unequivocally showed that the sequence derived from clone CD613 was highly homologous but novel and distinct from all other E1 -alpha BCKDH peptides listed in the data banks, from both prokaryotic and eukaryotic origin. In addition, the novel Streptomyces avermitilis E1 -alpha BCKDH peptide sequence encoded by gene bkdA (see Denoya, CD., 1993, "Cloned genes encoding branched-chain alpha-ketoacid dehydrogenase complex from Streptomyces avermitilis". U.S. Patent Application 08/100,518 filed July 30, 1993) was also compared. From this analysis, it was concluded that the 550 bp S. avermitilis genomic PCR product cloned in E. coli strain CD613 represents indeed a novel E1 -alpha bkd gene fragment. (f) Cloning of the whole S. avermitilis bkd gene cluster, restriction and Southern blot analyses, and construction of chromosomal map. As described above, the original 0.55 kb PCR fragment contains an internal 0.35 kb Sail fragment. This small fragment was used as a radioactively-labeled probe to screen a S. avermitilis genomic DNA cosmid library by colony hybridization. Ten clones were identified and recovered. Restriction and Southern blot hybridization analyses showed that the ten clones contain overlapping sequences originating from the same chromosomal region. The same probe was used at high stringency against Southern blots of digested chromosomal DNA from S. avermitilis ATCC 31272 SC2. The latter analysis confirmed the identity of the clones recovered from the genomic library. Surprisingly, two of the cosmid clones hybridized also to a bkdA specific probe (see Denoya, CD., 1993, "Cloned genes encoding branched-chain alpha-ketoacid dehydrogenase complex from Streptomyces avermitilis". U.S. Patent Application 08/100,518, filed July 30, 1993) suggesting that the bkd gene described here (named bkdF) may be located near the gene cluster comprising bkdA, bkdB. and bkdC A restriction map of the genomic region containing the S. avermitilis CD613 sequence was constructed (Figure 2). As predicted from the hybridization data discussed above, the bkdF gene is separated from the bkdABC gene cluster by only 12 kilobases. (g) Subcloning of genomic DNA fragments derived from cosmid clones and DNA sequencing of the S. avermitilis chromosomal region carrying bkd gene cluster. BamHI and Pstl genomic fragments, covering the entire CD613 bkd region of the S. avermitilis chromosome, were subcloned from DNA library cosmid clones into the E. coli vector pGEM-3Z. A list of the subclones constructed during this work, including a brief description of each plasmid, follows: 1. Plasmid pCD740 contains a 2.3 kb BamHI fragment; 2. Plasmid pCD854 contains a 1.4 kb BamHI fragment; 3. Plasmid pCD713 contains a 4.1 kb BamHI fragment; and 4. Plasmid pCD747 contains an approximately 5 kb Pstl insert. (Escherichia coli strains CD740, CD854, CD713 and CD747, corresponding, respectively, to the above 4 plasmids, were deposited in the American Type Culture Collection. The relevant information concerning these deposits can be found on PCT form RO/134, which is incorporated herein as page 55 of this application). In addition, a subclone containing an approximately 3.1 kb Pst I/Barn HI fragment was derived from the 4.1 kb BamHI fragment carried in plasmid pCD713. The new construct was recorded as plasmid pCD746 and it was used for DNA sequencing, as described below. Plasmid restriction mapping, Southern hybridization, and PCR analysis confirmed the identity of each subclone. (h) Computer analysis of DNA seguencing data obtained from cloned DNA fragments and identification of S. avermitilis E1 -alpha. E1-beta. and E2 bkd open reading frames. DNA sequencing data was obtained from a number of different subclones and constructs, as follows: 1. CD613: Represents the original PCR clone described in Sections "c" and "d" above and in the Examples 2 and 3. It contains part of the Open Reading Frame 1 (ORF-1 ) which corresponds to the bkdF gene encoding the E1 -alpha component of the BCKDH complex (Figure 3). 2. CD746: Represents the 3.1 kb Pstl/BamHI fragment derived from pCD713 (see section "g" above). DNA sequencing data, obtained by sequencing the Pstl end of the pCD746 insert using the SP6 vector primer (purchased from Promega Co.), revealed part of the ORF-2 which corresponds to the bkdG gene encoding the E1-beta component of the BCKDH complex (Figure 4). 3. CD785: Transposon mini-gamma-delta-1 insertion used to sequence DNA regions located downstream of the bkdF open reading frame in the cloned 4.1 kb BamHI genomic fragment. This mini-gamma- delta-1 insertion, named "A3", was located approximately 1.7 kb from the BamHI end containing the bkdF gene. DNA sequencing performed from both ends of insertion A3 (see EΞxample 6C) showed the presence of an ORF corresponding to the end of the E1-beta ORF (ORF-2) (bkdG) (Figure 5). 4. CD786: Transposon mini-gamma-delta-1 insertion used to sequence DNA regions located downstream of the bkdF open reading frame in the cloned 4.1 kb BamHI genomic fragment. This mini-gamma- delta- 1 insertion, named "A5", was located approximately 3 kb from the BamHI end containing the bkdF gene. DNA sequencing performed from both ends of insertion A5 (see Example 6C) showed the presence of an ORF corresponding to the end of the E2 ORF (ORF-3) (bkdH) (Figure 6). Sliding base composition analysis of the sequenced genomic region containing the S. avermitilis E1 -alpha, E1-beta and E2 (partial) bkd open reading frames (ORFs) was performed using the "DNA Inspector" software (Textco, N.H.). This analysis provided a profile of the running average of the G+C content using a stretch length of 30 bases and an offset value of 20. Overall G+C content corresponding to this region of the S. avermitilis chromosome was 69%. The G+C content as a function of codon position was also analyzed. Open reading frames were detected by using the program "CodonPreference" (Genetics Computer Group, Madison, Wl) with a Streptomyces codon usage table for 64 genes (F. Wright and M. J. Bibb, 1992, Gene. 113:55-65). The CodonPreference program is a frame-specific gene finder that tries to recognize protein coding sequences by virtue of their similarity to a codon frequency table or by the bias of their composition (usually GC) in the third position of each codon. ORFs were shown as boxes beneath the plot for their respective reading frames. All start (ATG) and stop codons were also detected (vertical lines). Rare codons found in each reading frame were marked below each ORF plot. The G+C content was calculated by using a sliding window of 25 codons, so a lag of about 25 codons was expected before the full impact of a protein coding region was observed. Three profiles were obtained, as follows: 1 , First position in triplet; 2, second position in triplet; 3, third position in triplet. As a result of this analysis, three bkd ORFs were located, corresponding to the following BCKDH subunits: E1 -alpha, E1-beta, and E2. (i) Construction of a S. avermitilis bkd mutant. The technique used for introducing the deletion is a variation of the gene replacement methods used in Saccharomvces cerevisiae. Escherichia coli. and Bacillus subtilis (Scherer, S. and R. W. Davis, 1979, Proc. Natl. Acad. Sci. U.S.A.. 76:4951-4955; Shortle, D., et al., 1982, Science. 217:371-373; Stahl, M.L, and Ferrari, E., 1984, J, Bacteriol .. 158:411-418). A general description of this technology, specifically applied to Streptomyces. can be found in the review paper "Genetic Manipulation of Streptomyces: Integrating Vectors and Gene Replacement", by Kieser, T., and Hopwood, D. A. (1991 , Methods in Enzvmology. vol. 204, 430-458). Furthermore, a detailed description of this technique, including an additional protoplasting step, necessary to assure single colony isolates and to increase the frequency of plasmid elimination, can be found in the paper by Anzai et a]., entitled "Replacement of Streptomyces hygroscopicus genomic segments with in vitro altered DNA sequences", Journal of Antibiotics. 1988, vol. XLJ, No. 2, pp. 226-233. A crucial step to the development of a mutated industrial strain by gene replacement is the construction of an integration vector that will work efficiently in that particular strain. In addition, when replacing genes in the Streptomyces chromosome, one of the major problems is elimination of the vector. Escherichia coli plasmids with selectable markers for Streptomyces might seem ideal because they cannot replicate in Streptomyces. E. coli plasmids have been used successfully in S. ambofaciens and S. lividans (Kieser, T., and Hopwood, D. A., 1991 , Genetic Manipulation of Streptomyces: Integrating Vectors and Gene Replacement, in: Methods in Enzymology, vol. 204, 430-458). However, in our experience this strategy showed a low efficiency of integration in S. avermitilis. resulting mostly in single crossover events. We have recently developed a number of versatile shuttle vectors useful for cloning both in Streptomyces and in E. coli. and for a variety of applications in molecular genetics technology in Streptomyces (CD. Denoya, 1993, "Novel Bacterial Plasmid Shuttle Vectors for Streptomyces sp. and Escherichia coli". U.S. Patent Application 032,925, filed March 18, 1993). These shuttles are structurally stable and replicate efficiently in E. coli and in a number of Streptomyces species, allowing transfer of a wide size range of cloned DNA fragments back and forth from one host to another. Three of the shuttle vectors (pCD262, pCD385, and pCD500) carry a Streptomyces temperature sensitive origin of replication that controls for a moderate-to-high copy number in Streptomyces. The temperature sensitivity of this replicon allows its application in Streptomyces gene replacement and mutant design experiments. Shuttle vectors pCD262 and pCD500 were successfully employed in the construction of the bkd-deficient strain described here. This vector is stably maintained as an autonomously replicating, high copy number plasmids in S. avermitilis. However, when a strain of S. avermitilis that has been transformed with any of these vectors is submitted to stress conditions, such as high temperature, sporulation, or protoplasting and regeneration, numerous plasmid-free colonies can be recovered. We have taken advantage of this characteristic to use either pCD262 or pCD500 as an integration vector in gene disruption experiments in S. avermitilis. The mechanism of the gene replacement in S. avermitilis is presumably a double crossover or a single crossover leading to integration and a subsequent resolution step where the integrated plasmid is excised. We have observed both double and single crossover events in S. avermitilis. Both mechanisms, double crossover and single crossover, followed by excision, result in the same product. By using this approach we were able to disrupt the E1 -alpha open reading frame corresponding to the bkdF gene of the S. avermitilis bkd gene cluster described here. The disruption involved a chromosomal deletion of about 1.4 kb affecting the 5'-half of the gene encoding the E1- alpha subunit of the BCKDH complex. The resulting mutant strain, which exhibits all the characteristic phenotypical traits of a bkd mutant, is stable and can be used to generate valuable novel avermectin products by fermentation. More specifically, we constructed a bkdF mutant by replacing a segment of the E1 -alpha BCKDH gene (bkdF) in the S. avermitilis ATCC 31272 SC2 chromosome with the ermE gene (for eythromycin resistance) from Saccharopolvspora ervthraea. As mentioned above, this was achieved by using a novel bifunctional __ coli/Streptomyces) vector (pCD262) that proved to work efficiently in both cloning and gene replacement experiments in S. avermitilis. As shown in Figure 7, three adjacent BamHI restriction fragments in the S. avermitilis chromosome were mapped (from left to right): 2.3 kb, 1.4 kb and 4.1 kb. The 1.4 kb BamHI genomic fragment carries the beginning of the E1 -alpha open reading frame (ORF-1) (gene bkdF). The 4.1 kb BamHI carries the rest of the bkd gene cluster (end of bkdF. bkdG. and bkdH). Plasmid pCD768 is a derivative of shuttle vector pCD262 carrying two S_, avermitilis genomic fragments (2.3 and 4.1 kb BamHI) which flank the 1.4 kb BamHI fragment (Figure 8). In addition, pCD768 carries the ermE marker located between the 2.3 and the 4.1 kb BamHI fragments. The ermE marker lies in the opposite orientation to that of the ORF-1 (bkdF). to avoid possible difficulties caused by overexpression of downstream genes. This construct is expected to produce a 1.4 kb deletion (ORF-1 will be affected) in the host genome upon recombination. Plasmid pCD768 was transformed into S. avermitilis ATCC 31272 SC2 host protoplasts. Two transformants resistant to both erythromycin (erm-R) and thiostrepton (tsr-R) antibiotics were selected (see Example 9). Transformant #1 (CD783) was grown in liquid medium and protoplasts were prepared and plated on agar medium containing erythromycin. Fifty clones were selected and further analyzed: 46 were erm-R, tsr-R; 4 were erm-R, tsr-S (pp15, pp17, pp22, and pp40). Four clones from the latter group as well as 2 clones from the former group (pp14 and pp21 , see Table I in Example 9) were further analyzed. All of them exhibited a bkd-deficient phenotype, as follows: All 4 erm-R, tsr-S clones were unable to grow on ILV minimal medium plates; had no activity when assayed for the E1 component of the BCKDH complex; and, upon fermentation, were unable to synthesize natural avermectins unless supplemented with either S(+)-2-methylbutyric acid or isobutyric acid (see Example 9). In addition, when CHC was added to the fermentation medium, novel avermectins (CHC avermectins) were synthesized, demonstrating that the bkd block did not affect the avermectin biosynthetic cellular machinery (see Example 9). One clone out of this group of 4 (clone pp15) was formally named S. avermitilis strain CD794 and is being deposited in the American Type Culture Collection as exemplification of this invention. Finally, Southern hybridization analysis clearly confirmed that ORF-1 corresponding to the bkdF gene was disrupted as expected upon gene replacement in S. avermitilis ATCC 31272 SC2 (see Example 5). EXAMPLES The following are detailed examples of the experimental procedures used to identify, clone and analyze the bkdFGH genes from S. avermitilis. which are also illustrated in the accompanying Figures. In addition, the construction of two bkd- deficient mutants by gene replacement are also described. Additional details of standard techniques, which are well known to those skilled in molecular biology, and the designation of the particular enzymes used, are described, for example, in the laboratory manual "Molecular Cloning" by Sambrook et al. (Cold Spring Harbor Laboratory, 1989). EXAMPLE 1 Preparation of S. avermitilis Genomic DNA S. avermitilis ATCC 31272 SC2 (single colony isolate #2) mycelium was grown as a confluent lawn on YPD-2 agar medium for 7 days at 29 °C The medium comprised: pH adjusted to 7.0. Final volume: 1 L Autoclaved for 25 minutes at 121 °C The mycelium was then used to inoculate 30 ml of AS-7 medium (see Hafner et a]., 1988, European Patent Application #88300353.5, publication # 0284176) in a 300- ml baffled flask, which was maintained with shaking (230 rpm) at 29° C for 24 hours. The medium comprised: pH adjusted to 7.2 with NaOH. Final volume: 1 L. Autoclaved for 25 minutes at 121 °C. 1 Prepared by hydrolysis of starch with "termamyl", an alpha-amylase from Bacillus licheniformis available from Novo Enzymes, Wilton, CT, to a dextrose equivalent of approximately 40%. - From Yeast Products, Inc., Clifton, NJ 07012. 3 From Traders Protein, Memphis, TN 38108. Approximately 0.3 ml of the above culture was used to inoculate another 300-ml baffled flask containing 30 ml of modified liquid Yeast Extract Malt Extract (YEME) medium (Bibb, M.J., Freeman, R. F., and D. A. Hopwood, 1977, Mol. Gen. Genetics. 154:155-166). Modified YEME medium contained per liter: Difco Yeast extract 3 g Glucose 10 g Autoclaved for 40 minutes at 121 °C 2 ml of 2.5 M MgCI 2 *6H 2 0 were added after autoclaving. Final volume adjusted to 1 L. Cultures were grown for 48-72 hours at 29 °C. Mycelia were recovered by centrifugation and genomic DNA was prepared following the protocol "Isolation of Streptomyces Total DNA by Caesium Chloride Gradient Centrifugation: Procedure 2", as found in the textbook "Genetic Manipulation of Streptomyces. A Laboratory Manual", The John Innes Foundation, Norwich, U.K., 1985, by D. A. Hopwood et al. DNA pellets were resuspended in 3 ml TE buffer (10 mM Tris-HCI, pH 8.0, 1 mM EDTA). EXAMPLE 2 Polymerase Chain Reaction of S. avermitilis Genomic DNA Amplification S. avermitilis genomic DNA was enzymatically amplified by using a Perkin-Elmer Cetus thermal cycler. The PCR reaction was carried out with Tag polymerase (Perkin- Elmer Cetus) and the buffer provided by the manufacturer in the presence of 200 micromolar dNTP, 0.5 micromolar of each primer, 50 ng of template DNA, and 2.5 units of enzyme in a final volume of 100 microliters for 30 cycles. The thermal profile of the first cycle was: 95°C for 3 min (denaturation step), 55°C for 2 min (annealing step), and 72 °C for 2 min (extension step). The subsequent 29 cycles had a similar thermal profile except that the denaturation step was shortened to 1.5 min. DNA primers were supplied by Genosys Biotechnologies, Inc. (Texas). The Rightward primer (Figure 1) was 5'-AAGAATTCGAGCTCGGCGACGGCGCCACCTCCGAGGGCGAC-3', and the L e f t w a r d p r i m e r ( F i g u r e 1 ) w a s 5 ' - AAGGATCCTCTAGAGGTSSWGTGGKGGCCGATSCGGWA-3'. The International Union of Biochemistry (IUB) rules of nomenclature for nucleotides were used to describe DNA sequences. Redundancies are identified following the IUB Group Codes, as follows: K=G+T, S=G+C, and W=A+T. Restriction recognition sequences not homologous to the E1 -alpha bkd genes and incorporated into the primers for cloning purposes are underlined (see Figure 1). The amplification products were size fractionated by agarose gel electrophoresis. The PCR sample was electrophoresed in a horizontal 1% agarose gel in 1 X TBE buffer (90 mM Tris-HCI, pH 8.5, 90 mM Boric acid, 2.5 mM EDTA) for 1.5 hours at 100 V as described by Sambrook et al., 1989, "Molecular Cloning: A Laboratory Manual", 2nd Edition, Cold Spring Harbor Lab, N.Y. The separated PCR DNA products were located in the gel by staining with ethidium bromide and visualizing fluorescent bands with a 365 nm ultraviolet light. Under the PCR conditions described above, a single DNA band (approximately 550 base pairs long) was detected when using this primer combination. EXAMPLE 3 Cloning of a 0.55 kb PCR Amplified S. avermitilis Genomic DNA Fragment into E. coli vector, and Subsequent transformation into E. coli host. A. Recovery of the 0.55 kb PCR Product As mentioned before, a 0.55 kb DNA fragment was amplified by PCR using S avermitilis genomic DNA as template and the Rightward plus Leftward primer combination. As shown in Figure 1 the Rightward primer has an EcoRI recognition site located at the 5' end and the Leftward primer has a Xbal recognition site at the 5' end. The 0.55 kb PCR fragment was cloned using a ligation procedure where both insert and cloning vector were digested with EcoRI and Xbal. Following amplification (as described in Example 2), approximately 80 microliters of the PCR reaction mixture was loaded on a 1% agarose gel and electrophoresed. The 0.55 kb DNA fragment was visualized as described before and recovered by electroelution as follows: The 0.55 kb DNA band was removed using a razor blade and the DNA recovered from the agarose gel by electroelution for 35 min. at 80 V into a V-shaped well filled with 7.5 M ammonium acetate using an unidirectional electroelutor (International Biotechnology Inc., New Haven, CT). The DNA was then precipitated with ethanol, pelleted and finally redissolved in 20 microliters of DNA buffer (10 mM Tris-HCI, 4 mM NaCI, 0.1 mM EDTA; pH 7.5). B. EcoRI and Xbal Restriction Enzyme Digestions The total amount of PCR material recovered above was digested simultaneously with 1 unit each of the restriction enzymes EcoRI and Xbal as recommended by the supplier (Boehringer Mannheim Biochemicals). Similarly, approximately 1 microgram of the plasmid pGEM-3Z (Promega Corp., Madison, Wl) and 2 units of the restriction enzymes EcoRI and Xbal (all restriction enzymes were purchased from Boehringer Mannheim Biochemicals) were incubated in the assay buffer specified by the supplier, at 37° C for 4 hours, in a total reaction volume of 60 microlitres to produce linear molecules. Then, both the PCR fragment and the linearized vector were each separately extracted twice with an equal volume of phenol-chloroform, twice with an equal volume of ether, and finally the DNAs were precipitated by adding 2 volumes of absolute ethanol. Precipitated DNAs were recovered by centrifugation at 10,000 x g for 10 min. and dried under vacuum. The final PCR fragment pellet was redissolved in 20 microliters of DNA buffer, and the final linearized vector pellet was redissolved in 12 microliters of DNA buffer. C. Ligation to Produce pCD613 About 11 microliters of the EcoRI/Xbal-treated 0.55 kb PCR DNA product, and about 1 microliter of the EcoRI/Xbal-linearized pGEM-3Z were incubated overnight with 1 unit of ligase (New England Biolabs, Inc. , Beverly, MA) under the conditions specified by the supplier at 15°C in a total reaction volume of 20 microliters. The reaction was terminated by placing the assay microtube on ice and the reaction mixture (20 microliters) was then used to transform competent E. coli DH5-alpha cells following the standard procedure described by Sambrook et a[., 1989, "Molecular Cloning: A Laboratory Manual", 2nd Edition, Cold Spring Harbor Lab, N.Y. Many ampicillin- resistant transformants were recovered. Plasmid vector pGEM-3Z contains a DNA segment derived from the jac operon of Escherichia coli that codes for the amino- terminal fragment of beta-galactosidase [Yanisch-Perron.C, Vieira, J., and J. Messing, Gene. 33, 103, 1985] . This fragment, whose synthesis can be induced by isopropylthio- beta-D-galactoside (IPTG), is capable of intra-allelic (alpha) complementation with a defective form of beta-galactosidase encoded by the host. E. coli cells exposed to the inducer IPTG synthesize both fragments of the enzyme and form blue colonies when plated on media containing the chromogenic substrate 5-bromo-4-chloro-3-indolyl-beta- D-galactoside (X-gal). Insertion of foreign DNA into the polycloning site of the plasmid inactivates the amino-terminal fragment of the beta-galactosidase and abolishes alpha- complementation. Therefore, bacteria carrying recombinant plasmids give rise to white colonies. Numerous white colonies were recovered from this transformation experiment. These colonies should contain the plasmid pCD613. This was confirmed by selecting one colony, designated as strain CD613, and further analyzing. A single bacterial colony of E. coli strain CD613 was inoculated into Luria-Bertani (LB) liquid medium containing 50 micrograms/ml of ampicillin following standard microbiological procedures. The LB medium comprised: Bacto-tryptone 10 g Bacto-yeast extract 5 g NaCI 10 g pH adjusted to 7.0 with 5 N NaOH. Final volume of the solution adjusted to 1 L Sterilized by autoclaving for 20 min at 121 °C. The culture was incubated at 35 °C overnight. The following morning, the bacterial cells were harvested by centrifugation at 10,000 rpm for 5 min. at 4°C Plasmid vector was isolated from fresh harvested Escherichia coli CD613 cells using a modification of the method of Birnboim and Doly (Nucleic Acids Res., 1979, 7:1513- 1523), as described by Denoya et al., (Microbios Lett.. 1985, 29:87-93). The isolated plasmid DNA was finally dissolved in DNA buffer (10 mM Tris-HCI, 4 mM NaCI, 0.1 mM EDTA; pH 7.5) to produce a concentration of approximately 1 microgram of pCD613 per 10 microliters of buffer. Confirming restriction analysis, using EcoRI and Xbal. showed that, as expected, pCD613 carried the 0.55 kb DNA insert. EXAMPLE 4 Preparation of Uniformly Radiolabeled Double-Stranded DNA Probes Double-stranded DNA probes were prepared by nick translation (see Sambrook et al., 1989, "Molecular Cloning: A Laboratory Manual", 2nd Edition, Cold Spring Harbor Lab, N.Y.), for a general description of this technique). First, a specific DNA fragment carrying the target sequence was prepared by appropriate restriction digestion and purification by electroelution essentially as described in Example 1. Approximately 1 microgram of DNA was labeled in each case using [alpha- 3 P]dCTP (deoxycytidine 5'-triphosphate,tetra(triethylammonium) salt, [alpha- 32 P]-) purchased from NEN-Dupont, and the BRL Nick Translation System purchased from BRL Life Technologies, Inc., following the instructions obtained from the supplier. A typical reaction was performed in a volume of 50 microliters. After addition of 5 microliters of Stop buffer (as described in the BRL recommended procedure), the labeled DNA was separated from unincorporated nucleotides using a Stratagene push column according to the supplier's instructions. 3 P-labeled DNA with a specific activity greatly in excess of 10 8 cpm/microgram was routinely obtained following these procedures. EXAMPLE 5 Analysis of S. avermitilis Genomic DNA by Southern Hybridization Approximately 10 micrograms of purified S. avermitilis genomic DNA were digested with 2 units of the restriction enzyme BamHI at 37 °C for a minimum of 2 hours. At the end of the digestion, the DNA fragments were separated by electrophoresis through a 1% agarose gel (see Example 1A), and were transferred overnight to a nylon membrane (pore size 0.45 micrometer) (Schleicher and Schuell Nytran membranes) using the capillary transfer method (Southern, E.M.,1975, J. Mol. Biol.. 98:503). The next day, the nylon membranes were wrapped in plastic wrap and the DNA side of each membrane was exposed to a source of ultraviolet irradiation (302 nm) to fix the DNA to the membrane. Hybridization of radiolabeled RNA or DNA probes to DNA immobilized on nylon membranes was performed following the protocol described in Sambrook et al. (1989), "Molecular Cloning: A Laboratory Manual", 2nd Edition, Cold Spring Harbor Lab, N.Y. (hereinafter referred to as "the Sambrook et a]. Manual"). Prehybridization and hybridization were carried out at 42 °C Hybridization solution contained: 6 x SSC (1 x: 0.15 M NaCI, 15 mM NaCitrate, pH 7.0), 10 x Denhardt's reagent [1 x: 0.02% ficoll, 0.02% polyvinylpyrrolidone, 0.02% bovine serum albumin] , 1 % SDS (sodium dodecyl sulfate), 100 micrograms/ml denatured, fragmented salmon sperm DNA, 100 micrograms/ml E. coli tRNA, and 50% formamide (Fluka). After overnight hybridization, membranes were washed as follows: two washes with 1 x SSC, 0.1% SDS, at room temperature for 15 minutes, and two washes with 0.1 x SSC, 0.1% SDS at 42°C for 15 minutes. In some experiments hybridization was carried out at 65°C in the absence of formamide, and SSPE (1x: 0.18 M NaCI, 10 mM NaP0 4 , pH 7.7, 1 mM EDTA) was used instead of SSC. Finally, membranes were exposed to X-ray film to obtain an autoradiographic image. EXAMPLE 6 DNA Seguencing A. Sequencing of Double-Stranded DNA PCR Product Carried in Plasmid PCD613 Supercoiled plasmid pCD613 was prepared as described in Example 2. Approximately 4 micrograms of double-stranded pCD613 were converted to a single- stranded form prior to seguencing. This was accomplished by alkali denaturation as described in the Tag Track Seguencing Systems Technical Manual (Promega Co., fv * iison, Wl. Oligonucleotide seguencing primers were synthesized by Genosys B i o t e c h n o l o g i e s , I n c . ( T e x a s ) . V e c t o r p r i m e r 1 (5'-AAGGATCCTGCAGCCCAGTCACGACGTTGTAAAACGA-3') maps upstream of the EcoRI site of the pGEM-3Z multiple cloning site (MCS) (position 2689-2712), and primer 2 (5'-AAGGATCCTGCAGACAGCTATGACCATGATTACGCCA-3') maps downstream of the Hindlll site of the MCS (position 91-114). B. Cloning of the pCD613-derived 0.35 kb Sail S. avermitilis genomic fragment into bacteriophage M13 and DNA Seguencing As discussed before, restriction analysis showed that the PCR-derived genomic fragment CD613 contained an internal 0.35 kb Sail fragment. This 0.35 kb Sail S. avermitilis DNA fragment was cloned into bacteriophages M13mp18 for the preparation of single-stranded recombinant DNA to be used as templates in Sanger's dideoxy seguencing method (Sanger et a|., 1977, Proc. Nat. Acad. Sci. USA. 74:5463-5467). About 2 micrograms of plasmid pCD613, prepared following a miniprep procedure as described before, were digested with the restriction enzyme Sail at 37° C for 2 hours to release the 0.35 kb S. avermitilis genomic fragment. The digestion mixture was electrophoresed in a 1.2% agarose gel, and the 0.35 kb fragment was electroeluted and precipitated as described before. In addition, about 1 microgram of purified double- stranded replicative form (RF) M13mp18 DNA were digested with Sail, dephosphorylated with calf intestine alkaline phosphatase (CIAP) (purchased from Promega Corp., Madison, Wl), and finally ligated to the 0.35 kb DNA fragment as described previously. Purified RF M13 cloning vector was purchased from New England Biolabs. Ugation mixtures were used to transfect competent E. coli JM109 cells. Several white plagues were recovered. Two single white plagues from the mp18 transfection carrying the insert in opposite orientations were selected, phage grown and single-stranded DNA was prepared as described in the Sambrook et a|. Manual. DNA seguencing of each single-stranded DNA template was performed using the M13- specific -40 seguencing primer (New England Biolabs, Catalog No. 1212), deoxyadenosine 5'-[alpha-thio]triphosphate, [ 35 S] (NEN-Dupont), and the TagTrack seguencing kit (Promega), following the instructions provided by the supplier (Promega). C. Transposon-Facilitated Seguencing of Some Genomic Regions Located on the cloned 4.1 kb BamHI Fragment Carrying Part of the bkdF Gene Mini-gamma-delta-1 transposon insertions were used to seguence DNA regions located downstream of the bkdF open reading frame in the cloned 4.1 kb BamHI genomic fragment from S. avermitilis. The mini-gamma-delta-1 element is a small (1.8 kb) gamma-delta (Tn1000) derivative that contains the kan gene from Tn5 and the resolution (res) site from gamma-delta cloned between two 40-bp inverted repeats of one of gamma-delta ends (Berg, CM. et al., 1992. Gene. 113:9-16. Mini-gamma-delta-1 lacks the genes encoding transposase and resolvase, and therefore depends on its host to supply transposition and resolution functions. Thus, in strains lacking the helper transposon, mini-gamma-delta-1 will not transpose and the insertion will be stable. Internal to the inverted repeat ends are unigue seguences that can be used as primer-binding sites for DNA seguencing. Transposon insertions were prepared essentially as described by Berg CM. et al., (1993, Methods in Enzymology, Academic Press, vol. 218, p. 279-306). Each inserted transposon was used as the initial template to seguence Streptomyces DNA located at both sites of the insertion. Two "universal" primers were used: "res" primer (5'-GTAGGGAGCCTGATATG-3'), and "kan" primer (5'- GCTATCCGCGCATCCAT-3'). Two mini-gamma-delta-1 insertions, named "A3" (clone CD785) and "A5" (clone CD786) were located approximately 1.7 kb and 3 kb from the BamHI end containing the bkdF ORF, respectively. DNA seguencing performed at both ends of each insertion showed that the A3 insertion (seguence CD785) is near the end of the E1-beta ORF (bkdG) (Figure 5), and the A5 insertion (seguence CD786) is near the end of the E2 ORF (bkdH) (Figure 6). EXAMPLE 7 Cloning of the whole bkd S. avermitilis gene cluster and construction of chromosomal map About 4 micrograms of purified pCD613 were restricted using Sail restriction enzyme and DNA fragments were separated by electrophoresis in a 1.2% agarose gel. An approximately 0.35 kb Sail DNA fragment, carrying seguence specific for the S. avermitilis bkdF E1 -alpha gene, was recovered by electroelution, and was labeled by nick translation as described previously. The [ 32 P]-labeled DNA fragment was then used as a probe to screen a S. avermitilis genomic cosmid library. A detailed description of preparation of genomic libraries in general can be found in the Sambrook et al. Manual. A complete description of streptomycetes chromosomal library preparation is presented in Genetic Manipulation of Streptomyces A Laboratory Manual by Hopwood et a[. (1985). A description of cosmid vectors is found in "Cosmid Vectors for Streptomyces Genomic DNA Cloning" by Denoya C. D., U.S. Patent Application 048,719, filed April 16, 1993. Ten clones were identified after screening more than 2200 recombinant library clones. The ten hybridizing clones (recorded as E. coli clones CD519, CD521 , CD691 , CD692, CD694, CD695, CD696, CD697, CD698, and CD699) were grown in LB liguid medium and plasmid was prepared from each culture as described before. Restriction and Southern blot hybridization analyses revealed that the ten clones were related, having overlapping chromosomal regions. Interestingly, two of the cosmid clones listed here, namely CD519 and CD521 , were also included in the list of cosmid clones identified using a bkdA probe (see C. D. Denoya, U.S. Patent Application 08/100,518, referred to above). A S. avermitilis genomic restriction map, covering the entire chromosomal region including seguence CD613, was obtained following standard procedures, and is presented in Figure 2. This Figure also shows the linkage between the novel bkd genes described here, and those described previously (C D. Denoya, U.S. Patent Application 08/100,518, filed July 30, 1993). Both bkd gene clusters are located approximately 12 kb apart. EXAMPLE 8 Transformation of Streptomyces lividans with Shuttle Vectors and Large Scale Preparation of Plasmid Vectors from S. lividans Transformants S. lividans strain TK64 was used in these experiments. The media for growing and protoplasting S. lividans. and the preparation of protoplasts and transformation were performed as described by D. A. Hopwood et al., Genetic Manipulation of Streptomyces - a laboratory manual, 1985, The John Innes Foundation, Norwich, U. K. In addition, the latter reference provides a full description of S. lividans strain TK64. Ϊ lividans protoplasts transformed directly with shuttle vector pCD262, or with a number of derivatives, were selected for thiostrepton resistance. Plasmid DNAs were prepared from selected transformants as follows: Cultures were grown in liguid YEME medium (Bibb, M.J., Freeman, R. F., and D. A. Hopwood, 1977, Mol. Gen. Genetics. 154:155- 166). YEME medium contained per liter: 3 g yeast extract, 5 g bacto-peptone, 3 g malt extract, 340 g sucrose. After autoclaving, 2 ml of 2.5 M MgCI 2 *6H 2 0 were added. Cultures were grown for 40-48 hours at 30° C Mycelium from 500 ml culture of streptomycetes cells were harvested by centrifugation, and resuspended to a final volume of 50 ml with lysozyme solution (2 mg/ml lysozyme in 0.3 M sucrose, 0.025 M Tris-HCI (pH 8.0), and 0.025 M EDTA). After this step, plasmids were prepared following an alkaline lysis procedure, essentially as described in the manual: "Genetic Manipulation of Streptomyces. A Laboratory Manual", The John Innes Foundation, Norwich, 1985. DNA pellets were redissolved in 500 ml 10 mM Tris-HCI, pH 8.0, 1 mM EDTA, and further purified by caesium chloride-ethidium bromide gradient ultracentrif ugation essentially as described in the Sambrook et a|. Manual. The isolated plasmid DNA is finally dissolved in DNA buffer (10 mM Tris-HCI, 4 mM NaCI, 0.1 mM EDTA; pH 7.5) to produce a concentration of approximately 1 microgram of plasmid DNA per 10 microliters of buffer. EXAMPLE 9 Construction of a S. avermitilis bkdF mutant The technigue used for introducing the chromosomal deletion is a variation of the gene replacement methods used in Saccharomvces cerevisiae. Escherichia coli. and Bacillus subtilis (Scherer, S. and R. W. Davis, 1979, Proc. Natl. Acad. Sci. U.S.A.. 76:4951-4955; Shortle, D. et al., 1982, Science. 217:371-373; Stahl, M.L, and Ferrari, E., 1984, J. Bacteriol.. 158:411-418). A general description of this technology, specifically applied to Streptomyces. can be found in the review paper "Genetic Manipulation of Streptomyces: Integrating Vectors and Gene Replacement", by Kieser, T., and Hopwood, D. A., 1991 , in: Methods in Enzymology, vol. 204. 430-458. Furthermore, a detailed description of this technigue, including an additional protoplasting step, necessary to assure single colony isolates and to increase the freguency of plasmid elimination, can be found in the paper authored by Anzai et al., entitled "Replacement of Streptomyces hvgroscopicus genomic segments with jn vitro altered DNA seguences", published in The Journal of Antibiotics, 1988, vol. XU, No. 2, pp. 226-233. The protoplasting and regeneration step often stimulates plasmid loss. However, most of the bifunctional (E. coli/Streptomyces) vectors (such as pCD262, used in this work) give rise to occasional plasmid-free cells after one or two rounds of nonselective growth (Kieser, T., and Hopwood, D. A., 1991 , in: Methods in Enzvmoloov. vol. 204, 430-458). A. Construction of Shuttle Vector Carrying Inactivated Copy of the bkdF Gene As shown in Figure 7, three adjacent BamHI restriction fragments in the S^. avermitilis chromosome region comprising the bkd gene cluster discussed here were mapped (from left to right): 2.3 kb, 1.4 kb and 4.1 kb. The 1.4 kb BamHI genomic fragment carries the beginning of the E1 -alpha open reading frame (ORF-1) (bkdF). The 4.1 kb BamHI carries the rest of the bkd gene cluster (end of bkdF. bkdG. and bkdH). Each of these three restriction fragments were subcloned into E. coli vector pGEM-3Z. The resulting constructs were: Plasmid pCD740, carrying the 2.3 kb BamHI fragment; plasmid pCD854, carrying the 1.4 kb BamHI fragment; and plasmid pCD713, carrying the 4.1 kb BamHI fragment (see Figure 2). The construction of the vector carrying the inactivated copy of the bkdF gene was carried out in two steps. First, both the 4.1 kb BamHI S. avermitilis fragment and the 1.6 kb Bglll fragment carrying the ermE marker, which confers resistance to the antibiotic erythromycin, were cloned into shuttle vector pCD262 (CD. Denoya, "Novel Bacterial Plasmid Shuttle Vectors for Streptomyces sp. and Escherichia coli". U.S. Patent Application 032,925, filed March 18, 1993) as follows: Approximately 1.5 micrograms of plasmid pCD713 was cut with the restriction enzyme BamHI and electrophoresed on a 0.8% agarose gel. After electrophoresis, the 4.1 kb BamHI fragment was recovered from the gel using the GeneCleanll kit and the procedures recommended by the manufacturer (Bio 101 Inc., La Jolla, CA ). Similarly, approximately 2 micrograms of plJ4026 was cut with the restriction enzyme Bgjll and electrophoresed on a 0.8% agarose gel. Plasmid plJ4026 is a derivative of the E. coli cloning vector pUC18 carrying the ermE gene of Saccharopolvspora ervthraea (formerly Streptomyces ervthraeus) (see M. Bibb et al., 1985, Gene. 41 :357-368, and D. A. Hopwood et al., Genetic Manipulation of Streptomyces - A Laboratory manual, 1985, The John Innes Foundation, Norwich, U. K.). After electrophoresis, the 1.6 kb Bgjll fragment was recovered from the gel using the GeneCleanll kit and the procedures recommended by the manufacturer (Bio 101 inc., La Jolla, CA ). In addition, an aliguot of purified plasmid pCD262 was linearized with the restriction enzyme Bgjll, dephosphorylated with calf intestine alkaline phosphatase (CIAP) (purchased from Promega Corp., Madison, Wl), and finally ligated to the 4.1 kb BamHI. and the 1.6 kb Bglll purified fragments described above. The ligation reaction was terminated by placing the assay microtube on ice and the reaction mixture (20 microliters) was then used to transform competent E. coli DH5-alpha cells following standard procedure as described in Example 1. Many ampicillin-resistant transformants were recovered. These colonies should contain the plasmid pCD761. This was confirmed by selecting one colony, designated as strain CD761 , and further analyzing the recombinant plasmid recovered from this strain with several restriction enzymes. Plasmid pCD761 is a derivative of the shuttle vector pCD262, carrying both the 4.1 kb S. avermitilis BamHI genomic fragment, and the 1.6 kb Bgjll DNA fragment carrying the ermE marker, both oriented as shown in Figure 7. Secondly, plasmid pCD761 was linearized with Bglll, dephosphorylated using CIAP, and ligated to the 2.3 kb BamHI S. avermitilis fragment isolated from plasmid pCD740. The ligation reaction was terminated by placing the assay microtube on ice and the reaction mixture (20 microliters) was then used to transform competent E. coli DH5-alpha cells following standard procedure as described in Example 1. Many ampicillin-resistant transformants were recovered. These colonies should contain the plasmid pCD768. This was confirmed by selecting one colony, designated as strain CD768, and further analyzing the recombinant plasmid recovered from this strain with several restriction enzymes. Plasmid pCD768 is a derivative of shuttle vector pCD262 carrying two S. avermitilis genomic fragments (2.3 and 4.1 kb BamHI) which are adjacent on each side of the 1.4 kb BamHI fragment on the wild type chromosome. In addition, pCD768 carries the ermE marker located between the 2.3 and the 4.1 kb BamHI fragments. The ermE marker lies in the opposite orientation to that of the ORF-1 (bkdF). to avoid possible difficulties caused by overexpression of downstream genes. This construct produces a 1.4 kb deletion, affecting the 5' end of the bkdF gene, in the host genome upon recombination. B. Transformation of Streptomyces avermitilis with Shuttle Vectors Shuttle vectors (pCD262, pCD768) used to transform S. avermitilis protoplasts were prepared either from transformed E. coli DH5-alpha or E. coli CD167 cells (strain CD167 is a single colony isolate derived from E. coli GM2163 -which was obtained from Dr. B. J. Bachmann, Curator, E. coli Genetic Stock Center, Yale University-) (see Example 1) or from transformed S. lividans TK64 cells (see Example 8). S. avermitilis strain ATCC 31272 single colony isolate #2 (SC2) was used throughout. Three alternative inocula were used to prepare S. avermitilis protoplasts: 1. Spores (prepared as described by Hopwood et al., 1985, Genetic Manipulation of Streptomvces - A Laboratory Manual, The John Innes Foundation, Norwich, U. K.), 2. Frozen Sonicated Mycelia (see preparation below), and 3. Colonies on YPD-2 agar (see Example 1). Frozen sonicated mycelia were prepared as follows: Mycelial cultures were grown in Trypticase Soy Broth (TSB) to a turbidity of 2 to 9 at 600 nm and then homogenized 10 times with a glass tissue grinder. The homogenized mycelia were diluted two-fold in TSB and 20 ml was added to a sterile polypropylene centrifuge tube. An ultrasonic probe (Bronwill Biosonik III) was submerged to a depth of 1 to 2 cm into the liguid, and the sample sonicated at 50% intensity (half maximum wattage) for 10 sec. Sonication dispersed the mycelial masses into single or double cellular units which produced rapid exponential growth when subcultured. Sonicated mycelial preparations were diluted to a final concentration of 40% glycerol, pipetted into vials, and frozen at -85° C. Spores, mycelia, or homogenized colonies were inoculated into YEME medium (see Example 1 ) containing 0.5% glycine. Preparation of S. avermitilis protoplasts and transformation protocol were performed as described by D. A. Hopwood et aj, Genetic Manipulation of Streptomyces - A Laboratory Manual, 1985, The John Innes Foundation, Norwich, U. K., following modifications as described by MacNeil, D. J., and Klapko, L M., J. Industrial Microbio 1987, 2, 209-218. S, avermitilis protoplasts transformed with shuttle vector pCD262, or a derivative such as pCD768, were selected for thiostrepton or erythromycin resistance, respectively. C Isolation of S. avermitilis Ervthromycin-Resistant. Thiostrepton-Sensitive Mutant using pCD768 Plasmid pCD768 was transformed into protoplasts of S. avermitilis 31272 SC2 as described above. Primary transformants of S. avermitilis were selected with 4 micrograms of erythromycin per ml on regeneration medium (RM14) plates (see above for reference describing the media composition). Two erythromycin-resistant (erm-R) transformants (Nos. 1 & 2) were picked onto YPD-2 agar plates (see Example 1) containing either 4 micrograms/ml of erythromycin or 4 micrograms/ml of thiostrepton. Both transformants were resistant to both antibiotics (erm-R, tsr-R). Transformant #1 (named S. avermitilis strain CD783) was selected for further work. This strain was grown in YEME liguid medium and protoplasts were prepared and plated on regeneration medium plates containing erythromycin (4 micrograms/ml). This protoplast regeneration step was included to assure single colony isolation and also to increase plasmid loss (Anzai, H., et al., 1988, "Replacement of Streptomyces hygroscopicus genomic segments with in vitro altered DNA seguences", The Journal of Antibiotics, vol. XjJ, No. 2, pp. 226-233). Numerous colonies were regenerated and fifty clones were picked onto plates containing erythromycin or thiostrepton. Forty-six out of fifty colonies were able to grow on thiostrepton. Summarizing, 46 colonies were erm-R, tsr-R, and only 4 colonies were erm-R, tsr-S. The erm-R, tsr-S colonies presented the phenotype expected after the integration had formed (double crossover events) and the free replicon had been lost. Therefore, the 4 clones that presented the erm-R and tsr-S phenotype (pp15, pp17, pp22, and pp40), together with 2 clones that were erm-R, tsr-R (used as control) (pp14, and pp21), were further analyzed. D. S. avermitilis bkdF Mutant: Phenotype of S. avermitilis Carrying a Chromosomal Deletion Affecting the 5' End of the bkdF Gene The following analysis were performed: 1. Ability to grow on minimal media agar plates containing isoleucine, leucine, and valine (ILV) as sole carbon (C) sources; 2. Assay of Branched Chain Alpha-Ketoacid Dehydrogenase (BCKDH) E1 activity; and 3. Ability to produce natural and novel avermectins during fermentation. A description of these methods follows: 1. ILV Plates: A variation of the classical M9 minimal medium (Anderson, E. H., 1946, Proc. Natl. Acad. Sci. U.S.A.. 32:120-128) was used. The modified M9 medium comprised (per liter): Agarose (SeaKem ME, FMC BioProducts, Rockland, ME) 7.5 g Distilled H20 650 ml Autoclaved for 15 minutes at 121 °C When cooled, the following sterile solutions were added: 25 x M9 Salts solution 40 ml Mineral stock solution 2.1 ml 0.1 M FeS0 4 .7H 2 0 0.1 ml ILV mix 250 ml pH adjusted to 7.0 Final volume: 1 liter. Approximately 25 ml were poured per plate. 25 x M9 salts was made by dissolving the following salts in deionized H 2 0 to a final volume of 1.2 L: K 2 HP0 4 125 g NaH 2 P0 4 -H 2 0 55 g NaN0 3 48 g pH adjusted to 7.0 The salt solution was divided into 160-ml aliguots and sterilized by autoclaving for 15 minutes at 121 °C. Mineral stock solution comprised: 1 M MgS0 4 *»7H 2 0 1 M CaCI 2 0.25 M MnS0 4 «H 2 0 Autoclaved for 15 minutes at 121 °C ILV mix was prepared by dissolving 10 g each of L-isoleucine, L-leucine, and L- valine in 1 L deionized H 2 0. Mix was sterilized by filtration. On these plates bkd-deficient mutants were unable to grow. ILV nonutilizers were scored after 14 days incubation at 29° C. 2. BCKDH E1 Assay: BCKDH E1 activity was determined by a modified version of the radiochemical assay described previously (Hafner, E. W. et aj., 1991 , Antibiotics. 44:349-356). Selected isolates were grown on YPD-2 agar plates for 6-7 days at 29°C After growth, a "pinhead" sized clump of cells was picked up from each colony growing on the YPD-2 agar plates using a sterile toothpick and transferred to the bottom of a 15-ml glass scintillation vial. The cells were resuspended and permeabilized by the addition of 100 microliters of the toluene/alpha-[1- 14 C] ketoisocaproate mix (prepared as described later). The mouth of the vial was immediately covered with Whatman 4CHR paper (Whatman catalog number 3004614) that has been impregnated with Solvable (a tissue and gel solubilizer purchased from NEN-Dupont). A plastic cap was then firmly placed on the vial, both the cap and the upper half of the vial were wrapped with parafilm, and incubated with gentle shaking for 3.5 hours at 29°C At the completion of the incubation, the filter paper was transferred to a 7-ml glass scintillation vial containing 4 ml "Ready Safe" (Beckman) liguid scintillation cocktail to determine radioactivity. Radioactivity was measured after eguilibration in this solvent for 4 hours or more. The toluene/alpha-[1- 1 C] ketoisocaproate mix was prepared by adding 22 microliters of the alpha-[1- 14 C] ketoisocaproate stock solution to 1 ml M9 salts medium (Davis, R.W., et aj., 1980, Appendix 1 : Media, drug concentrations, and nutritional supplements In "A Manual for Genetic Engineering - Advanced Bacterial Genetics", p. 203, Cold Spring Harbor Laboratory, N.Y.) containing 5% toluene which had been sonicated to produce a milky- white dispersion of the toluene. The alpha-[1- 1 C] ketoisocaproate stock solution was prepared by mixing 2.8 microliters of 20 mM alpha-ketoisocaproate (sodium salt, Sigma K-0629), 50 microliters of alpha-[1- 14 C] ketoisocaproate (55 mCi/mmol, 50 microCuries/ml, Amersham), and enough H 2 0 to a final volume of 1 ml. Protein concentration was determined by using the Bio-Rad protein assay (Bio-Rad Laboratories, Richmond, California), which is based on the Bradford dye-binding procedure (Bradford, M., Anal. Biochem.. 72:248, 1976). The specific activity of the E1 component of the branched-chain alpha-ketoacid dehydrogenase is expresed as picomoies of C0 2 evolved per minute per milligram of protein (Table I). 3. Avermectin Production: Either S. avermitilis ATCC 31272 SC2 or S^ avermitilis strain CD794 (bkdF) mycelium grown on a fresh, modified YPD-2 agar plates (the modification consisted of the omission of acetate from the regular YPD-2 medium, see Example 1 ) for five to seven days was inoculated into a 50-ml (1 x 6 inch) culture tube containing 8 ml of minimal defined medium (see below). The tube was then shaken at a 45° angle at 200 RPM at 29°C for 72 hours. After growth, a 2-ml aliguot of the seed culture was used to inoculate a new 300-ml flask containing 25 ml of minimal defined medium to which various additions of fatty acids could be made. The fermentation medium was made up as described previously (Hafner, E. W. et a[., 1991 , J. Antibiotics. 44:349-356) except that hydrolyzed starch (114 g/liter) was used instead of thinned and potato soluble starch, leucine and NaCI were omitted, and glycine (2 g/liter) was added. In some fermentations, either S(+)-2-methylbutyric acid or cyclohexane carboxylic acid (CHC) were added to the medium (0.04% final concentration). After 12 days of shaking (200 RPM) at 29°C, the flask contents were extracted with 4 volumes of an acetonitrile-methanol (7:118) solvent mixture and the supernatant was analyzed for avermectins by high performance liguid chromatography (HPLC). The HPLC assay was carried out using a Beckman 5 micrometers Ultrasphere ODS C-18 column (4.6 mm x 25 cm), with a flow of 0.75 ml/minute and detection by absorbance measurements at 240 nm. The mobile phase was water (178 ml), acetonitrile (102 ml), and methanol to a final volume of 2 liters. Table I below summarizes these results. The four thiostrepton-sensitive clones, which have lost the free replicon, exihibited a typical bkd-deficient phenotype, as follows: All 4 clones were unable to grow on ILV minimal medium plates and had no activity when assayed for the E1 component of the BCKDH complex. Fermentation studies showed that the blocked cultures were unable to synthesize natural avermectins. In addition, when S(+)-2-methylbutyric acid was added to the fermentation medium (0.04%) final concentration), natural "a" forms of avermectin were synthesized; similarly, addition of cyclohexane carboxylic acid (CHC) led to the formation of novel CHC-avermectins. These fermentation results demonstrated that the bkd block did not affect the avermectin biosynthetic cellular machinery. One clone out of this group of 4 (clone pp15, see Table I) was formally named S. avermitilis strain CD794 and was deposited in the American Type Culture Collection as an example of this invention. The relevant information concerning this deposit can be found on PCT form RO/134, which has been incorporated herein as page 55 of this application. TABLE strain ATCC 31272; PF402-77, a bkd-deficient mutant derivative of strain ATCC 31272 SC2 and produced by chemical mutagenesis; CD783, a derivative of strain ATCC 31272 SC2 transformed with plasmid pCD768 (see Example 9); pp14-40, single colony derivatives of CD783 isolated after protoplasting and regeneration (see Example 9). b Erm-R, resistant to erythromycin; Tsr-R, resistant to thiostrepton. c + or -, ability or inability to grow on minimal medium supplemented with Isoleucine, Leucine, and Valine, as sole carbon sources. The specific activity of the E1 component of the branched-chain alpha ketoacid dehydrogenase as picomoles of C0 2 evolved per minute per milligram of protein. e The results are the means of duplicate determinations. f + or -, production of non-production of natural avermectins by fermentation. g 0 = not dectable. h NT, not tested. i -/+ = non-production of natural avermectins by fermentation; however, production of natural avermectin when S(+)-2-methylbutyric acid was added to the fermentation medium and production of novel CHC-avermectins when CHC was added to the fermentation medium. E. Southern Hybridization Analyses to Confirm the bkd-minus Genotype Southern hybridization analyses were performed on two of the erm-R, tsr-S clones, pp15 (formally named strain CD794) and pp22 (formally named strain CD798). These analyses showed that chromosomal integration of the ermE marker, and concomitant deletion of the 1.4 kb BamHI genomic fragment that carries the 5' end of the bkdF open reading frame (ORF-1 ) had occurred by a double crossover. Restriction fragments of chromosomal DNA were resolved by electrophoresis through a 1% agarose gel and transferred to nylon essentially by the method of Southern (1975) as described in Example 5. EXAMPLE 10 Construction of a S. avermitilis bkdABCF Mutant This example describes the construction of a stable S. avermitilis multiple mutant affecting the following bkd genes: bkdA, bkdB. bkdC, and bkdF. The first three of these oenes-bkdA. bkdB. bkdC encode the E1 -alpha, E1-beta and E2 subunits of the branched chain alpha-ketoacid dehydrogenase complex, respectively. These genes are part of the bkdABC gene cluster, as described by Denoya, CD., U.S. Patent Application 08/100,518, filed July 30, 1993. The bkdF gene is located in the bkdFGH gene cluster described above, and encodes the E1 -alpha subunit of the branched chain alpha- ketoacid dehydrogenase complex. A. Design and Construction of Delivery Vector Carrying Target Chromosomal Region (bkdC) Marked with a Selectable. Antibiotic-resistance Marker (ermE) First, the 6.5 kb Sphl S. avermitilis 31272 genomic fragment (carrying the bkdABC gene cluster) was subcloned into the Sphl cloning site of shuttle/delivery vector pCD500 (see Denoya, CD., "Novel Bacterial Plasmid Shuttle Vectors for Streptomycetes and Escherichia coli". U.S. Patent Application 08/032,925, filed March 18, 1993), resulting in plasmid pCD544 (see Figure 9). Subseguently, the 1.7 kb Bglll plJ4026 fragment carrying the ermE marker was inserted into the unigue Bgjll site present in the pCD544 insert. Plasmid plJ4026 is a derivative of the E. coji cloning vector pUC18 carrying the ermE gene of Saccharopolyspora erythraea (formerly Streptomyces ervthraeus) (see M. Bibb et a[., 1985, Gene. 41 :357-368, and D.A. Hopwood et aL, Genetic Manipulation of Streptomyces - A Laboratory Manual, 1985, The John Innes Foundation, Norwich, U.K.). The resulting construction (pCD547) has an insertionally inactivated copy of the bkdC gene. B. Construction of a Genetically Marked bkdC Mutant Strain Using plasmid pCD547 as the delivery vector (see previous section), S. avermitilis wild type strain ATCC 31272 SC2 as the host, and following standard gene replacement procedures (see Example 9), twelve protoplasted/then regenerated single colonies showing an erythromycin-resistant thiostrepton-sensitive phenotype were selected. One colony out of this group of 12 was formally named S. avermitilis strain CD570 (see Figure 9), and it was used as a host in the following gene replacement steps (see below). C Design and Construction of Delivery Vector Carrying Mutated (deleted) bkdABC Target Region Plasmid pCD728 is a derivative of shuttle vector pCD262 (see Denoya, CD., "Novel Bacterial Plasmid Shuttle Vectors for Streptomycetes and Escherichia coli". U.S. Patent Application #08/032,925, filed March 18, 1993) carrying two S. avermitilis chromosomal fragments (7 kb BamHI. prepared from subclone pCD528, and 6.5 kb Bglll/BamHI. prepared from subclone pCD559 (see Figure 9). For a full description of the subclones utilized here see also Denoya, CD., U.S. Patent Application 08/100,518, filed July 30, 1993. D. Construction of Unmarked. bkdABC Deleted Strain Plasmid pCD728 was transformed into protoplasts of S. avermitilis strain CD570 and putative transformants were recovered. A control plasmid, pCD739, with one of the genomic fragments inserted in the wrong orientation, was also introduced in strain CD570 by transformation. Many recombinants were obtained in which the ermE marker had been replaced by the bkdABC deleted construct and the delivery plasmid (pCD262) had been lost from the cells. Summarizing, upon transformation and double crossover recombination, pCD728 produced a deletion of about 2 kb of the S. avermitilis chromosome affecting bkdA (E1 -alpha), bkdB (E1-beta), and bkdC (E2) genes. The recovered integrants had an erythromycin-sensitive, thiostrepton-sensitive phenotype. Southern blot analysis confirmed that the ermE marker was replaced by the deleted seguence. One single colony, representative of this group, was selected for further work and recorded as strain CD757 (see Figure 9). E. Design and Construction of the bkdF Gene Replacement Vector The construction of this vector was described in Example 9, section A. Briefly, plasmid pCD768 is a derivative of shuttle vector pCD262 carrying two S. avermitilis genomic fragments (2.3 and 4.1 kb BamHI) which are adjacent on each side of the 1.4 kb BamHI fragment on the wild type chromosome. In addition, pCD768 carriers the ermE marker located between the 2.3 and the 4.1 kb BamHI fragments. The ermE marker lies in the opposite orientation to that of the ORF-1 (bkdF). to avoid a possible lethality caused by overexpression of downstream genes. This construct produced a 1.4 kb deletion (affecting the 5' end of the bkdF gene) in the host genome upon recombination. F. Construction of a S. avermitilis Multiple bkd Mutant (bkdABCF) Plasmid pCD768 was transformed into protoplasts of S. avermitilis strain CD757 (bkdABC) (see step D, above) essentially as described in Example 9. Many transformants were recovered and putative integrants were selected following the standard protocol. One integrant, representative of this group and showing an erythromycin-resistant, thiostrepton-sensitive phenotype was named strain CD797 and further analyzed (see Figure 9). Culture CD797 exhibited a typical bkd-deficient phenotype, as follows: it was unable to grow on ILV minimal medium plates (see Example 9, and had no activity when assayed for the E1 component of the BCKDH complex. Fermentation studies showed that the blocked culture was unable to synthesize natural avermectins unless supplemented with either S(+)-2 methylbutyric acid or isobutyric acid. Also, addition of cyclohexane carboxylic acid (CHC) led to the formation of novel CHC-avermectins. These fermentation results demonstrated that the multiple bl<d block, comprising disruption or deletion of four bkd genes (bkdA, bkdB. bkdC and bkdF). did not affect the avermectin biosynthetic cellular machinery. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: DENOYA, CLAUDIO D. (FOR U.S. ONLY) STUTZMAN-ENGWALL, KIM J. (FOR U.S. ONLY) PFIZER INC. (FOR ALL COUNTRIES OTHER THAN U.S.) (ii) TITLE OF INVENTION: GENES ENCODING BRANCHED-CHAIN ALPHA-KETOACID DEHYDROGENASE COMPLEX FROM STREPTOMYCES AVERMITILIS (iii) NUMBER OF SEQUENCES: 8 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: DR. PETER C. RICHARDSON, PFIZER INC (B) STREET: 235 EAST 42ND STREET, 20TH FLOOR (C) CITY: NEW YORK (D) STATE: NEW YORK (E) COUNTRY: U.S.A. (F) ZIP: 10017-5755 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Paten In Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: US 08/168,602 (B) FILING DATE: 16-DEC-1993 (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: DEBENEDICTIS, KAREN (B) REGISTRATION NUMBER: 32,977 (C) REFERENCE/DOCKET NUMBER: PC8529A (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (212)573-5425 (B) TELEFAX: (212)573-1939 (C) TELEX: N/A (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 501 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: TACGTCTTCC CGACCTACCG CGAGCACGGC GTCGCCTGGT CCGGCGGGGT CGACCCCACC 60 AACCTGCTCG GCATGTTCCG CGGCGTGAAC AACGGCGGCT GGGATCCCAA CAGCAACAAC 120 TTCCACCTCT ACACGATCGT CATCGGCTCG CAGACGCTGC ACGCCACCGG CTACGCCATG 180 GGTATCGCCA AGGACGGCGC CGACTCGGCC GTGATCGCGT ACTTCGGTGA CGGCGCCTCC 240 AGCCAGGGTG ACGTCGCCGA ATCGTTCGCC TTCTCCGCGG TCTACAACGC CCCTGTCGTC 300 TTCTTCTGCC AGAACAACCA GTGGGCGATC TCGAGCCCCA CCGAGAAGCA GACCCGCGTC 360 CCGCTCTACC AGCGCGCGCA GGGCTACGGC TTCCCGGGCG TCCGCGTCGA CGGCAACGAC 420 GTACTGGCCT GCCTCGCCGT CACCAAGTGC CTCGAGCGGG CCCGCCGGGG CGAGGGGCCC 480 ACGTTGGTCG AGGCGTTCAC G 501 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 201 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: CTCGCCGAGT CGGGCATCGT CGGCACGGCG ATCGGTCTCG CCCTGCGCGG CTACCGGCCG 60 GTGGTGGAGA TCCAGTTCGA CGGCTTCGTC TTCCCGGCGT ACGACCAGAT CGTCACGCAG 120 CTCGCGAAGA TGCACGCGCG GGCGTCGGGC AAGATCAAGC TCCCCGTTGT CGTCCGCATC 180 CCGTACGGCG GCGGCATCGG C 201 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 217 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: CGCCGGTGTT CCTGGGCGGC GGGCCGCCGG AGATCGCCGC CCGCATCACG GAGCGCTGCT 60 TCTACCACCT GGAGGCACCC GTGCTGAGGG TCGGCGGCTA CCACGCCCCG TATCCGCCGG 120 CGCGTCTGGA AGAGGAGTAC CTTCCGGGCC TTGACCGGGT GCTCGATGCC GTCGACCGCT 180 CGCTGGCGTA CTGAGGAGAG GGTCGTGACG ACGATGA 217 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 453 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: AACCAGGAGA TCGTCCTCAA GCACTATGTG AACCTGGGCA TCGCGGCGGC CACCCCGCGC 60 GGTCTGATCG TCCCGAACAT CAAGGACGCC CACGCCAAGA CCGTGCCGCA ACTGGCCGAG 120 TCACTGGGTG AGTTGGTGTC GACGGCCCGC GAGGGCAAGA CGTCCCCGAC GGCCATGCAG 180 GGCGGCACGG TCACGATCAC GAACGTCGGC GTTCTTCGGC GTCGACACGG GCACGCCGAT 240 CCTATCCTCA ACCCCGGCGA GTCCGCGATC CTCGGCTTCG GCGCGATCAA GCTCCAGCCG 300 TGGGTCCACA AGGGCAAGGT CAAGCCCCGA CAGGTCACCA CGCTGGCGCT CAGCTTCGAC 360 CATCGCCTGG TCGACGGCGA GCTGGGCTCC AAGGTGCTGG CCGACGTGGC GGCGATCCTG 420 GAGCAGCCGA AGCGGCTGAT CACCTGGGCC TAG 453 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 167 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: Tyr Val Phe Pro Thr Tyr Arg Glu His Gly Val Ala Trp Ser Gly Gly 1 5 10 15 Val Asp Pro Thr Asn Leu Leu Gly Met Phe Arg Gly Val Asn Asn Gly 20 25 30 Gly Trp Asp Pro Asn Ser Asn Asn Phe His Leu Tyr Thr lie Val lie 35 40 45 Gly Ser Gin Thr Leu His Ala Thr Gly Tyr Ala Met Gly lie Ala Lys 50 55 60 Asp Gly Ala Asp Ser Ala Val lie Ala Tyr Phe Gly Asp Gly Ala Ser 65 70 75 80 Ser Gin Gly Asp Val Ala Glu Ser Phe Ala Phe Ser Ala Val Tyr Asn 85 90 95 Ala Pro Val Val Phe Phe Cys Gin Asn Asn Gin Trp Ala lie Ser Ser 100 105 110 Pro Thr Glu Lys Gin Thr Arg Val Pro Leu Tyr Gin Arg Ala Gin Gly 115 120 125 Tyr Gly Phe Pro Gly Val Arg Val Asp Gly Asn Asp Val Leu Ala Cys 130 135 140 Leu Ala Val Thr Lys Cys Leu Glu Arg Ala Arg Arg Gly Glu Gly Pro 145 150 155 160 Thr Leu Val Glu Ala Phe Thr 165 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 67 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: Leu Ala Glu Ser Gly lie Val Gly Thr Ala lie Gly Leu Ala Leu Arg 1 5 10 15 Gly Tyr Arg Pro Val Val Glu lie Gin Phe Asp Gly Phe Val Phe Pro 20 25 30 Ala Tyr Asp Gin lie Val Thr Gin Leu Ala Lys Met His Ala Arg Ala 35 40 45 Ser Gly Lys lie Lys Leu Pro Val Val Val Arg lie Pro Tyr Gly Gly 50 55 60 Gly lie Gly 65 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 63 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: Pro Val Phe Leu Gly Gly Gly Pro Pro Glu lie Ala Ala Arg lie Thr 1 5 10 15 Glu Arg Cys Phe Tyr His Leu Glu Ala Pro Val Leu Arg Val Gly Gly 20 25 30 Tyr His Ala Pro Tyr Pro Pro Ala Arg Leu Glu Glu Glu Tyr Leu Pro 35 40 45 Gly Leu Asp Arg Val Leu Asp Ala Val Asp Arg Ser Leu Ala Tyr 50 55 60 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 150 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: Asn Gin Glu lie Val Leu Lys His Tyr Val Asn Leu Gly lie Ala Ala 1 5 10 15 Ala Thr Pro Arg Gly Leu lie Val Pro Asn lie Lys Asp Ala His Ala 20 25 30 Lys Thr Val Pro Gin Leu Ala Glu Ser Leu Gly Glu Leu Val Ser Thr 35 40 45 Ala Arg Glu Gly Lys Thr Ser Pro Thr Ala Met Gin Gly Gly Thr Val 50 55 60 Thr lie Thr Asn Val Gly Val Leu Arg Arg Arg His Gly His Ala Asp 65 70 75 80 Pro lie Leu Asn Pro Gly Glu Ser Ala lie Leu Gly Phe Gly Ala lie 85 90 95 Lys Leu Gin Pro Trp Val His Lys Gly Lys Val Lys Pro Arg Gin Val 100 105 110 Thr Thr Leu Ala Leu Ser Phe Asp His Arg Leu Val Asp Gly Glu Leu 115 120 125 Gly Ser Lys Val Leu Ala Asp Val Ala Ala lie Leu Glu Gin Pro Lys 130 135 140 Arg Leu lie Thr Trp Ala 145 150 Applicants or agenfs file International application No. Reference number PC8529A NOT YET ASSIGNED INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

Claims: CLAIMS 1. An isolated DNA segment that encodes for a branched-chain alpha- ketoacid dehydrogenase complex of an organism belonging to the genus Streptomyces. 2. An isolated DNA segment according to claim 1 that encodes for a Streptomyces avermitilis branched-chain alpha-ketoacid dehydrogenase complex. 3. An isolated DNA segment according to claim 1 , further comprising a DNA region that regulates the expression of said branched-chain alpha-ketoacid dehydrogenase complex. 4. An isolated DNA segment according to claim 2, further comprising a DNA region that regulates the expression of said branched-chain alpha-ketoacid dehydrogenase complex. 5. A DNA segment that comprises the DNA seguence of SEQUENCE ID NO. 1 , SEQUENCE ID NO. 2, SEQUENCE ID NO. 3 or SEQUENCE ID NO. 4, or an allelic variation of such seguence. 6. A DNA segment that is a subset of, and functionally eguivalent to a DNA segment according to claim 5. 7. Recombinant DNA comprising a DNA segment according to claim 5. 8. A host cell into which has been incorporated recombinant DNA according to claim 7. 9. A plasmid comprising recombinant DNA according to claim 7. 10. A DNA segment that is selected from the group consisting of pCD713, pCD740, pCD747, and pCD854. 11. A host cell into which has been incorporated a DNA segment according to claim 10. 12. A DNA segment according to claim 5 that comprises a DNA region that regulates transcription or translation of the DNA seguence of SEQUENCE ID NO. 1 , SEQUENCE ID NO. 2, SEQUENCE ID NO. 3 or SEQUENCE ID N0.4, or an allelic variation of such seguence. 13. The genes for branched-chain alpha-ketoacid dehydrogenase complex contained in a DNA segment according to claim 10. 14. A DNA segment comprising a DNA seguence that is a subset of the DNA seguence of SEQUENCE ID NO. 1 , SEQUENCE ID NO. 2, SEQUENCE ID NO. 3 or SEQUENCE ID NO. 4, or an allelic variation thereof, and that is capable of hybridizing to, respectively, SEQUENCE ID NO. 1 , SEQUENCE ID NO. 2, SEQUENCE ID NO 3 or SEQUENCE ID NO. 4, or an allelic variation thereof, when used as a probe, or of amplifying all or part of such seguence when used as a polymerase chain reaction primer. 15. A substantially purified polypeptide comprising the amino acid seguence of SEQUENCE ID NO. 5, SEQUENCE ID NO. 6, SEQUENCE ID NO. 7 or SEQUENCE ID NO. 8. 16. A polypeptide produced by expression in a host cell according to claim 8. 17. A method of producing a natural avermectin, comprising fermenting, under conditions and in a fermentation medium suitable for producing such natural avermectin, J avermitilis in which the copy number of a genomic fragment comprising one or more of the bkdF. bkdG and bkdH genes has been increased. 18. A method according to claim 17, in which S. avermitilis. in which the copy number of a genomic fragment comprising the bkdF. bkdG and bkdH genes has been increased, is fermented. 19. A method of producing a natural avermectin, comprising fermenting, under conditions and in a fermentation medium suitable for producing such natural avermectin, j avermitilis in which expression of a genomic fragment comprising one or more of the bkdF. bkdG and bkdH genes has been enhanced by manipulation or replacement of the genes responsible for regulating such expression. 20. A method according to claim 19, in which S. avermitilis in which expression of a genomic fragment comprising the bkdF. bkdG and bkdH genes has been enhanced, is fermented. 21. A method of producing a novel avermectin, comprising fermenting, under conditions and in a fermentation medium suitable for producing such novel avermectin, S. avermitilis in which expression of a genomic fragment comprising one or more of the bkdF. bkdG and bkdH genes has been decreased or eliminated by deletion, inactivation, replacement or other manipulation of the genes responsible for such expression. 22. A method according to claim 21 , in which S. avermitilis. in which expression of a genomic fragment comprising the bkdF. bkdG and bkdH genes has been decreased or eliminated by deletion, inactivation, replacement or other manipulation of the genes responsible for such expression, is fermented. 23. A method according to claim 21 , wherein genes that are deleted, inactivated, replaced or otherwise manipulated are enhancer, inhibitor, activator or repressor genes. 24. A method according to claim 21 of producing a novel avermectin, comprising fermenting, under conditions and in a fermentation medium suitable for producing such novel avermectin, S^ avermitilis in which a genomic fragment comprising one or more of the bkdF. bkdG. and bkdH genes has been deleted or inactivated. 25. A method according to claim 24, in which S. avermitilis in which a genomic fragment comprising the bkdF. bkdG and bkdH genes has been deleted or inactivated is fermented. 26. A method of producing a novel avermectin, comprising fermenting, under conditions and in a fermentation medium suitable for producing such novel avermectin, S^ avermitilis in which expression of a genomic fragment comprising one or more of the bkdA, bkdB and bkdC genes and one or more of the bkdF. bkdG and bkdH genes has been decreased or eliminated by deletion, inactivation, replacement or other manipulation of the genes responsible for such expression. 27. A method according to claim 26, in which S. avermitilis. in which of a genomic fragment comprising the bkdA. bkdB. bkdC and bkdF genes has been deleted or inactivated is fermented.

Inventors: DENOYA CLAUDIO DANIEL, STUTZMAN-ENGWALL KIM JONELLE, DENOYA, CLAUDIO, DANIEL, STUTZMAN-ENGWALL, KIM, JONELLE
Applicants: DENOYA CLAUDIO DANIEL, PFIZER, STUTZMAN ENGWALL KIM JONELLE, DENOYA, CLAUDIO, DANIEL, PFIZER INC., STUTZMAN-ENGWALL, KIM, JONELLE
Application year: 1994
Main classification: C12N15
IPC codes: C07K14, C12N1, C12N9, C12N15, C12P17, C12P19, C12P21, C12R1